var title_f13_49_14096="Bilateral DDH plain radiograph";
var content_f13_49_14096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Plain radiograph: Bilateral developmental dysplasia of the hips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 332px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFMAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyn4Y6lY3MFz4d1C1jlN4+6JWYL9oJABh3HhJDtVo37OMHKuccz4s0GXw/qfklzNaTL5lrcFCvmx5IyQfusCCrKeVZSD0rCBIPHUV61o+o2njzw3c2OszCLUbcGaadhkqwAH2wd+gVZ1HVQsoyUbIB5Rk564FTQjJGal1bTrrSdTuLDUIjDdQPsdDzz6gjgg9QRwQcimRcYoAtKewq3B1GQKpxA9hVuI/nQBpQGrkJ6Zxn0qjD2zVuM7cAdaANCN8L1qwjk1nxnJ5NW4W49KANGFwMcVdjQlsngHtVW1jA+Zufp2q4rBqANGFmhIjkUowxwetXUmOeMYJ/KsSORvMyzHOeSTya042+UYPP86ANCOXrkdKtwTElQMe1ZKOQRyfxq1E3HJ+tAHQQTYKg9TWjC4IAHasC3fpz+dasLEgbaAOisTv6ntWvGcDpk/zrCsjtVc9a2rZ1IJBBAHWgCURgtnHuAe1SxORIoYcUgyWU84qUL+8HA9qANW3KMqn05Ga0oXUHJ6msO1OARzwa1bZ1bAI7dKANJWBXKnI71bgjBw3eqMUew/J93HQ1owupQEHigCWimeameop4OaACmugYHgU6igCExHOQePSkcAZDVKzYqKR1xgnnPSgBic5wD14oXJODxz1x2pVOCcHjuKMDOc0ATBFxjFOCgdBUSuO5FPVweAQaAFKKeoB5z07+tRz529B9alLAKTVeaddhGKAM26YKCFHIPNVfMBTJB3U9yXLtGG7DnpkVXk4UlsnntQBVmc7T1+tYlzNksuDgcVrXbkLjHPb0rFcM8hweaAIdpfgA4zzVpIdsWGxxT4otrYpXO0Hjjv7UAZ12cY2jjrzWbKyNuxmr90+Sdox9axJmIkIH3TQAx2OSMmqzsev86dPJsYjBPpzVSSTpkjmgCG4cn5u3oKqSSqAT61JeMQpPQe1ZU8hPJoAhv1SXOBg1jvGVY7h0rQlfLDGee9NO11IfOfWgDHuAD6HnP0qhKTyc5q9dAq2OOOKzZXA60AVpc8g8ms24BGSfyq/JgAlSeeeeaoz55x+VAGdPkA1mXIDZyK1LgnnFZdzk8Ac0AZUylTUDGr0p4wQKoTrhuOlADOuO9NJopDmgAz78UU0k0UAWweT2q5pOoXWk6jbX+nzNBd27h45F7Ee3QjsQeCODVMYzjNKnPbBz0oA9e1KxtfH3hu2vNIiSLUoMQxQL1R8E/ZD3KkBmgY9g0XJVK8tGVOCCCOMVpeFNdl0HUvOEQntJV8q6tixUTRkgkZHKsCAysOVYAjpXbePtCi1Wz/4SPSHNw0kfn3DbQDcR5C/aMDgOGIWZR0Yhx8sgwAcBCcVbh4xzVOEfnVxBgDNAF6NucjpVlW496oI3TFWY2zxQBdjbp61oWgJYDqOp9qzImA+Unk1s2a7UyRyaANANgYBwO1P3AgcYx6VWU5apkxQBMD1NXreVdqgk89fastWzx0qzbN2zQBrIQcHP4VaiY7gRkis6Ns4FXIz+NAGpbyZYDuK1reUhBxWFbED161rwNgADn0oA6DTpC2AxOK6GDHk8AsOmK5ywThWretGJO3d07UAXwflAxgA5q1b43LkfQiqiA55Hfg1dtAM4PagC0h2MSSPmqxCW37lAOT60mxXjAxzUltHsIJ5x3oA0Y7jahLHcD6jGKzJLySO43K+B2FF8zMAkbEDqSO9UGjbrjPuaAOl0y6WccgbvStQDI4rmtKDRZd+BjgGtq2n3HHVe4PagCwzknbjmmmQ4Ck4pu3l33EhsDb2X6VXmDqp+bP0oAcX465PpTJZdwyeDUBY57k4/KopJzv2YbA744zQBOLgg/KeRSiQkY5BxWZPJhs8AD0qRZGbO3+WRQBbL9BuOafbOzvuGQf0qCNWYAHhant2RWGFJAP60AW5JiqMCBkVi6hePkhcKD1OetW551DkNj5u1YuqrIMMpyM5BoA0IbgeWV6Z6n1qnPIwPB4qha3LpKVkB2Hirdx2PXigCpKxbBAyO1Z78AsORnnFalvGGcjA4P51BdKBlcED6UAVoJGyeRgikuG+XHP1oVdnQdahuz8hB59c8UAULhlClhye9Yly5YYP6Vr38oZmKIFB52jtWFc3A3FRk5/SgCrdvz0PSqDy/KTnn0q7OcjpxWZcAYweaAK1xM2SM9KrSE7R0+pp0zYGCCD61WkbAOTxjigCrM3JJPNIrgj1HtTZPmfjkU1cE4OB70AQXi+ahIxkd6wrnjNb8mNxycisXUAqSZHQ0AZczFe1VZmBXPerU5znn3rPlIBPY0AVbjnPPNZtzkNk1oTNms656/SgCjL3qpOcr6ValIHH61Vk6mgCq3ynFFOccUygAJFFIaKALYxnFPUc8CmDrUi9M0ASKvNdp8PPFB0a6+xXspj06aTeJdnmfZZcFfM2fxIVJSRP40JHUKRxi/hmpRQB2/jvwyNJujfWUSpp8z7HiR/MFrKRu2Bv4kZSHjf8AiQjuGA5uIkACu4+H+uR6jaf8I9q0a3G6PyLZXcJ58ZO77MWPCsGO+Jj918qfldsc14k0STQ9RWMO01pMvm21wUK+bHkjlT91gQVZTyrKQelAFRMEDirMIwc1Sh6itCEcCgC3b8kA9a2IsYUDHSsq3AL54rUjGT2+tAFlflbGKlXDDrzUSgdqljU4PrQAYJJA61LCcEDP5UgXHT9KkSM9ccUAXYOnU9Kuxj8/YVDawZArRhT5gOlAEluCVBODjpWtaYypaqUUZVxjkVc2FgoHpQBv2koC8HBNa9oWdgVJB9R1rm7AyO21gcgda6SyIVAAfm9R0oA14Pm+XP1rQgjIXuAao2QIZcj8avpL5YORzn86AL8BPyn35qSd/m4BxVeKVGXbu4qZSGUng8UARDLEkdvelLYOB17mogfm+/gk8VYC7hkjn+dAD4jzuY5yfXmtG1Ecab1GCT6daz0kVTtYbW9cVN9pOQOwHFAGmj567s9xRIwBA5JFVo7kYG/86Uyh3yp/XtQBI5Cr/ez2qrJGvQ546H1p5OSckce/SmF1znJxQBCIwSQQMU7hBxxTTIVLFMEionnJbB6+lAF1XBwW4pG3B8g4BqqlxnCgD6UskpwMigBLsKWJ59jWfcuRwOfarckw2lXH0qmSTx1PvQBCMMAew5qV3AU5PXpUTAL1PT0qu8h3gHJBoAvwpgFgAMiq16OAcZIq0HCREHn3zVSdwwAU/L6UAVEBzwBye5qvOh5JHHeryoSpIYBe4xVO8AAbkY7igDImIwwx1/Subvk2ucHmujuCMFeKyL6INlsYIoAxZGYvuxyBVO5f5SCOT3q8+d5HUCql5HkhtwAFAGXMxI2n71VHGBzWg8Sum7Gcd6oyISW64IoAqtywKjGaBt55+YdaUYGF9O9JJwcgDBoArzcEcmsrUclc56da05uBknk81mXhwhoAw5x1IHFZ9x156GtG4JDHGCKzrlc520AUpGIHWqVxzViRuTzVZyDn1oApS5HrVZ+lW5hzVSQUAQN3psMMk86QwRvLNIwRERSzMxOAAB1J9Kv6Xpl5q+oQ2Gm273F3McJGnU8ZJJ6AAZJJ4AGTXqFla6N8OdKS+upRearcR/u5YJCrzgkgi3PWOE4Ia44dvuxYGXoAzLDwVpPh/QZ9Q8ZPunyU8lXIETgZ8ldpBkn6BgDsiB+clsJRXB+IddvtevRcX7qFjURwQRLsit4x0SNBwqj9SSTkkmigCBcGpFH5UxRUg6evtQA/9alSo1A9OalT/OaAJoyQQc/lXqmk6ha+MtAuLPV5RHeRDzppiMlWAA+1gdegVZgOqhZOSjZ8rj44rQ0m+udN1C3vLGVobqBw6OvYj+f0PWgC5fafc6ZqM9lfRmK5hYo6k5/EEcEEcgjgg5qSPp713t1Z23jHQ7afTYkjvYgIYIlPKPgn7IfVSAWhJ/2ouSqZ4RBjhuCOKALlp1wBitSHrzjFZVtw1a1tzQBbjAzxUyLk/LnFLHHgjd0qyoUcL0oAWOEbPep41wev4VGG4xkVKOdvAPvQBetl3D0Iq/D9cc81m2zAce9aduVI4yM9KANC2VWB9avW0Qzjis+2cdCPmrRgP3SxP5UAadkuHzn8617SNvNwCDnkZ6YrJtnAAJG49hW5Y7S4LAc/pQBr2akgKR8o71YkHOG4HaltlUMhzkcZNTOFD4HfuaAK6EFgAvNWoidyjqMdaqnCTjJ4P6VbwNuePp6UARy/LNkCrMTgpg8nPr/KqkzDcGxk+tT2xAxnk47UASXJDgEAgjoakt28wDeOahlbAJzSfbFilXaCfXFAGk2QuAKaDyDn6j0qL7SpU/MACORTi0R2tnLYwCD0zQAsjhW3EZpoYOSBxRJ5fc81GSiOcMM0AQSs0ZJ5yPSkMm4+/YVK7h8gbaRfLWQNjcRxz0oAWFcKcipZFC8v3quJAJM46flTppUklBLngYxQBUkDlyznaD075p4JVMBevciidxuGPlPTpUZYkZ5/CgCF2UMBzk1VQfv9uSBn1qa4GDkelRRLvkBBz7UATMcErnFGBtz/AJNNlUtMwz09as7ccDkYoAjLERHA/Ssm9Hl5aT16VvoFEbb8En1rA1ZQSc9PpQBl3LKAemev1rImc4bI9/pV+5kXB4z/AErOnbKAevp2oAzrhgmTjgn0rGu5TK7DnaeMVr3KkPtPOe+azrlPmyvc0AVICcEE8D1qOUKSemB1qVYwudx5PpUU34AevrQBWaIHJXgH8qrzRkjFXmYbTkgVBJgYJoAzLgYBBFY904ZHIOQDjit27GcjGD1xWLfR4U4AzQBhTnk1nynOevB/OtG4QhufxqhOpweOaAM2cc5qox5NXZxjNUZCaAK8uDnmrmgaDea9dyQ2gRIYl8ye5lO2K3T+87dh2AGSTgAEkCtfwn4UuvEU4di8GniVYXnWMuzyHpFEg5klI6KPqSoya6bxH4ps/C9kukeFkiS6hIfzYpBKltJjG8OOJrjk/vcbY+REP4yAP1W+0j4e6ZJptjALnVJkAliuEw0nQhrpf4U7rbdcgNKTwleT6rqF3quoT32o3ElzdztvklkOWY/54x2ps7tLI8krs0jklmY5JJ6k1Aw4oAY1FD9KKALqj2qRaYtSLQA9f1qUfnTFHNSDqKAJUqzCOQarxD5qvQD0FAG54b1STSbxpCnn2sq+Xc25YqJY8gkZHIIIBVhyrAEciuw8W6UmpW/9s6fIbiRk86ZwuPtMeQvn4HAcMQsqjoxDj5ZBjgIhjFdb4N1r+z5Ra3MxhtXk8yObZv8As0uCvmbf4lKkq6dHQkdcEAGNbLlh14rYtxhaveJtIFlKbu2iENuZAksCvvFtKRuCBv4o2Uh43/iU+oYDNikJUqOp60AaUbbgBT0JJ+neqsR9+KsKwI9z3oAsKe+MGpowSvB71XUjPX2qRCVx9aALUR+bHGRV+CXIHrWbE24kN2q1AcHnFAGzbuB8xGea0YJMdCTWLA4wuScGrwlCqGB6dqAN+2kRW+YnHbFb9g+WUgn3B4rkrGTzGU9PrXS2Lbmxu+uKAOjt5iCuAQOoz3rQXDR7t2e5Gaw4pGLnntWjZScFCDzwPSgBkkgEpyO/er3mhodw4OKzpVAkbPGD60xrnauw96ALKyh3POcd6ke4WJ8LyccjsKyop9m7bnPYUkQy2Sx+poAutPJJnbzT1Ug7nbiq54BwcY/WlWQkjnP1oA1A6OuB26VKHUJlgMk4xVaGMBQxwfQelRyM6jqcHpQBbMoxznnpVYs2/B5XqPanbwI+AAfagPwM9aAEY7JOSfWmSTZzyR/SlmkUgZ6jn6VVuXBPBx9aAJzMc5Q896Ys5jJLdTnis5JSrYGTk1NdK8fzcFiM4FAFuS7X5Tj26809XUqCpyD2rG84kg+vqKljmZW3KSKANKf7rDnGM/Sq9s37/kAHtStcb4GfocYNUFkzKgUcnnjrQBtSqFBJB9algbFrvbJI9aqvL5rnuSccVPczBY/LTGB3FAEAn5YtyT1rL1BgxIPQirTScEdzWXqG4THce3FAGNcuqEx469zVC5JjwvBOOtXLjDXGGHOM1m3DEzgEfnQBVuG3KxLcj0qpGyF8TA7PUdc1cmiXn51UE1DatDbXkc1xbrcRI25omYqH9iRQBnuTuP8AKoTzyeg7VYuXDzO4VUBYkKvQZ7Cq2cAk460AMmXcMcbT1BFVZZMN83brxU8zAjOapSsS3Hf86AK1zICx54rNvMbeKu3H51l3EmTjPHagCjMoIxgk1m3aHOQMVqyMRz39apXHOaAMWaMc56iug8K+DH1IpfaossenlWkjiV1jkuVX7zBm+WOJc/NK3yjoNzfLXQaH4XhtY2v9eEKmJVl+zzkiOBWBKvcY5+YcpCvzyf7K/NWB408Uy6sZbSyMsWnMV8wvgSXJUYUyBeFVcfJEvyIOBk5YgDvGHjRFgOl+HHSO2WM273MKGNfLJyYYFPzJETyzN+8kPLnHyjzp+OtWJRgn0qu/egCBgDULdOKncEVAfrQAw9KKGooAvKOR9KlUdgKYo4FSKPWgB496evTtTKliAb6UAWIVwauxAcEGq8SgVbhGRQBZiAz3NXIuAOtVUHIqdWIHWgDuPCmqi9iXSrtBPLs8mFGcKLmInd9nLHhWDZaJz918g/K7VlarYtpd0gjczWky+ZbzlSvmJkjlTyrAgqynlWUg9KwFfHTr613lhfW/iLSbiPUn2TJ+9upMZKMAB9sAHJ4AWYDkqFk5KNkAwYJM49Kto4I4qlPBPp17LZ3qeXcQttZcg/kRwQRyCOCDUsTj6UAX0GSBwBUoXlif0qnE4A4zViJwVJoAsRjCgjOe9Txsc8iq0R3Yz09KnH3ev4UAX4XDqMjBB61pQkFCGGRWVbLkAd/StO0A7cmgDWskRQDkhj2ro7FgoByOeMAVz1mf3fZWzwTW9aEZXkcdTQBrwN8wDZA6YrTt2Ve/PYViRNlxjsavxsWkGc8elAGjcHeHIxkCsjUCyqNw5I4q8WI5zkZ71m6pdLKjKuAQM9aAKlnKvnFS3UfrWnC43DceAea5lJWDjAz33Z6Vo2k7M/zcnGc0Abdxcr0UZHTnio4ZWLjaOPX1qnvzyBxUkUygfex7UAblrKzOqnAz1qSRY+TvxWTDeKnCcE9KdJclsAn3+tAFveu4AsOKZ9pzJuXAwetUy/ysG9M59aagQE4PXrQBfllUku77mJ5I61VkdW/iGM96pXkqhcKM/wAqqFyercduaANmLYApfGAc59akuZlDdCR2OetZ0UgeAqzcj2pXmGFSRsnHGO1ADZJIhIwGfxp7vvTPpVSTDDjgHrUHmlCQuaALNzctAhUc57VBp0zSXTMzfdXIqlczM8xPBOP0qxo3zySkkdMCgDpLJ+G3EFgOBUjPlSMDpk1SUmMLuHAH51JHISfvAn0NADJSVye9Z+oltm/qwGKs3jDBz09KqSOWTgbh0I70AYNwZXyBkH2FZ90PmyW59TW3cAKRgdD2NYd7tZuevcdqAKcjejbsGoJZBsPze1Em0k4J5NU5SC7Fs4oAbI2SST0PFRM45yeaHYBemfrUJkB46UANlweM8+9U5nHqPwqWZ/l5qhNKoIKmgCK4k27gT3rLkYOxJ6+tTXExcsQe9N06yuNRu0trOJpJmyQBwAAMliTwABkkngAZNAFeOOSaVIYUeaRyFREBLMT0AHc11+maXa+H7dtQ1KVRcxOUMqqsiwSA8xxKcrLOO5OY4v4tzYQTQrp/hrTxMZTLJPHxNESkt0pHSE9YoOoM3DyDITauXPGaxqVxqNwJLjy1SNRHDFEoSOGMdERRwqj0FADPEmtz6swjwYLKNmaO3Dl8MfvO7Hl5G6l25PsAAOauB171oyj5qpXAxQBj3KcVQkGDWtcJ68is+YYNAFR+arv1PNWW75qFhg9KAID9aKc1FAGgucelPUcdaavBwKkHSgBw5wKsRDioEAzVuMdMUAWIQc1cj45AqrHwc1YTk8GgCyp47U9e3+FRJzxing9+nNAE646/pVzT7yewvIbuzkaK4hYOjjsf6j271RUgipVwB1oA7+a2t/Eek2z6dGsc6YitYx/yyfk/ZD/snBaEn/ai6hM8nDMVYqw5HrRoWqNpd0zNGJ7SdPKubdiQJYyckZHIIIBVhyrAEciul8U6aL6D+1rOU3Ehj8+WQAA3UWQpnwOBIpIWVR0Yq4+WQYAMWJ8j9atxSZxxiseGb5Rk9KuwSBsHPPtQBrJJwAe1TxN/tYNUYWyetPUgNkk5HIoA2I2IAXIB65q9bOyMNw6+lYUUjqxzk5rRtpiwGSwxwTQB0toUM0TNkY445rbhYox4xH7965azmK4zWvb3W7gsfb0oA34pAFGDkZ4q/YSGZxuyFUZOaxYDnbzyOgzVrVbv7Fo8zAgNJ8oPpQBHr/iLfI1vZYSNRjI6msBZnYk7mOayln555PrViObPOaANSOXGcHkc4q3bXRQ89+1Y0cpLA54qzHJuUno1AHQC8XblevYVXmnLNu3HPoKy0lwo55qYHufyoA1IblgcDJGKsLc9O5J6Vn2v3flC575q5JboGDKCB3GaALK3G7P+z2qUy7jgjbnjiswMY5MMdq96n89CMFiQTmgCWUDdkMMd6rzIowc0s9zCu05OapzXSuwAPPtQBbQhEZizFjzx0qNp9uCOOc9KWHcUZz26Cq13KMAjg+1AA104kLE7ueaGu1djtOPas55gHxjB71UMu0570AXpZy0hOfxqFbp4yTGxH0qB5eAcc1WeQ4JJ4oA6vQ/Ee2QW9/8AvIm+UOeoNb10EgwYyTGwypry4ycEbsV2+g3ZvdGAkILxEA89RQBblmJDA856nNQs4VCB1qOYEyZH3R19qq3FwFyVwcDk0AV7t13M7sfMxgDsKxp3HCqDsHHzdSKsX83AOckj061mXEoC4PIxmgCOV9y5CDHTOapSHkgDHPNLPcsRjoB2qsJC3ToOtADJTtzzmqcsgxkdT1OalupBnk4rKuJSSdvFAEk8w2Ebj+FZdxPvb5SQKS5mIU45NXtD0WbU2WWXzYrMv5YeOPfJNJjPlxJ1d8c46KOWKjmgCvpemy6o8hV0ht7cCSe5lJWOFc43MfqQABkk8AEnFdPf3Nl4bszZxW7NOwBa1nUb3PUPdDkAA4K24JA4Mu4gKItY1yDR0is9JEIuYHLRmJvMjtH5G5X6Sz44M3RekYA+Y8UzliSxOScknuaAJb+8uL68lubyaSeeVtzyOclj71Sk9PSpGIOaick8UAV3Jzmqs2DVmTIz6VVkPNAFKfgVmzDkmtOXnr1qjMo5oAzpBgmoG6VakGBVZh+VAEBHrRTm96KANFenTqKkFMA4APpT16CgCWPqO9Woxjpz61XQHAq1F6igCZBjFToD1qJO9TL+lAEq1KuT6YqJTzUgxjBoAlHPYZqZQSOAc0yIdM9fSrXIGf5UAV2JFdF4R1v+zrgWt1M0VpI4kSYJv+zS4K+Zt/iUqSrp0dCR1wRiEZUDFRMCjYoA6fxTo39nztdW0IitmcJLCrbxbSkbgob+KNlIeN/4kPqGAy4XzgBsE10HhHVRewrpF6izyFDDbo7hRcRk7jbFjwrbiXic/dfg/K7Vj6tpx0u7VVdpbSYeZbzFSnmJkjlTyrAgqynlWUg9KAJ43I2nPNXVJ2cVmQOGAOfwqykpDigDQiYMQDn860LccZHFZEbZPJAFXo5QFGTQBsRTq2MHtir9pNtY5AOTxXPJLjHer9vMd/B4oA6uCbod2SeCM1F4suFWyto1PDc4PWqVrKdq4456GoPFkpZbc8EgUAZSy4AI7VZglyQenrWOk3zfTmrdtLyAc0Aawc5z0FWbeXJxmssSZIpyzfNx2oA1C2Hzzj61Yhmxgk5HSs3z8R5OOPWopb6ME4OB2oA6u1uI4jljx0OKmn1DdnYPl9a42LUgGwTx2xWil0CvB460AaE187MQ30qNbg5yOtUWuk2neM5GKWCUZzwwPY9qALryCWNg0u1gPlGM7jn9KgWV4pMyE8dAO9RSXGCDt47j1qZZkkwSOcUAXorxipB+63HNVry4y21RnHYVTubp1HygAD1rMkuJNx+YjPU0AaSSp526bdgggbSM57VBcSBZDtbgHIJFUdzY649vWklXOAT+VAF8y7kB4NV5HOCAfwqDzMLt/SomkPf9aAFeQAE8g10vgq6b7RLECNrL0NcdNNgdefetnwjPjUCc/wABoA6u9ulEzCP6day7i5wCM/WkupVMrHcR71mXEoOcH3oAkuJQ6BVOcH8azZmLoVzxnPWnSuedpFQs24HnHGOKAKs7jJxzj9ajL4BJ4zSyL845xzVSeUBm28jOOtAEV25Zzn7tZc7kD0J6VbupQFJzk1saZoqWoa61cRLNEFdorgMYrZT9158YLMf4YFIdup2p8xAKGg6A10Y7rUEbyHUyRW4fy2mVThpGY8RwqRhpD9FDNxS6/wCIhta10tx/q/Ie5jUovl94YVPMcWepPzydXJ4AreIvEMmoebBbGVbWRlaR5cebcsowrSFcDAHCooCoOAOpPOtywHSgBVBJHrStGx4I61Mo2YwBt7+ppW3Y9KAKmNrc/lUUmc5NWZRlDnr2qkx7UARyEdOv0qpNjtirMnB96rS9eT+lAFKUD1qrNjmrkgH0xVOYflQBQlBB+tVXHbtV6YDn1qnKKAIDRSPwKKANJDuA+lSIOajXt9KkQ896AJ4+3c1aj7EVXQDirCjNAEyHngip0GOKhT8hU8SlmIwaAJFJqZEY4NSQWxz82Pxq2keD047UANhgOBxVgL26GnxLgcmrKBSOnNAFIrhvQVDNw31rSmUGPIA9Kz504zQBDyCCOPeu90++tvEuj3MWpPsnj/e3UmMlCAALwAcnAAWYDkqFk6o2eT8PaJqPiDUVsNHtTdXRUuEDqvA68sQP8ScVZ0LT9XhtJ/EGlNFHHpsq75TcxI6MfujYzbmzyOAQcEc4NABJaz6ZfzWd6hS4hbayk5HsQe4IwQe4OaVCOSD3rpZbe38S6RbPpyJHOhENtEP+WT4J+xn/AGTy0B/3ouyZ5FJCzEgbXBwVPrQBqRsCQG644q9HnyxnqtZkTq4HIBHUHvWhESvbg96AJfMw3FW7dyPSqjLkZA4pyNgY9KAN6zuWOMccd6drzMdPjyCNp7jnkVl2sw3D24rTu5murGRXLM+3gn0HagDnFbDHrVmCXac+tUpDtOQMU+IkkYNAGs0vAx171Kh7sTgDNUFbIAPanzTbYTtPNAC3d6Sdo6dqgjSRxkg+tQWYWWcs/b3q+XwQB24xQAC2yoOdr+uatQySxr2xyKbboWGCc56VNJGFjJ5OKAIjOfMwTitCGQEAMffjrWLJjcS4IqxblgAWJ9jQBuxkFckZ9KQybWJyM+9Z0UmDjd8p604SqSwJ5oAmuXZR6k1UdwxGBg0gcuWwSO+PWnJhuTwB1oAiLHJIGSPWgsTjjkdaWRTuJXJqs5OCwPAoAkZ8nkc9QfWobiTB7jvUckvAGelQTyZTA69aAEnkyo9a2fDPEssmTwtc6JCXBI5HNdHov7q0MjYBc80AXbibGQTx3zVGaYYPIpLmTc5zxVViqgHOTQAPLubAwB14o3cHPAPc1EpwD0FKcyqeyqMnPAAoArSsefas9RLPdJDAhllkYKkaDLMx6AAd6txxzX9yLXT082ZwSTkKqKBkkseAoHJJwB3rTMlh4d0/zN7yNOnDqTHLeKQeE6NFbkcF+JJR93ah3EAdbWtnokDX1zMnnozIbhMOIpB1jgByskoJwznKRf7b4UclrWsS6i6oo8mzjLNFbqxYBmOWdmPLyN1Z2yzHqegFuC01jxdfT/Y7fz2tbbzPKj2xpBAmAFRcgBRkAKPyJqmmh38mgy6yiwf2dFKIXf7TGG3novl7t5JGTwOgJ6A0AZmR9cU6IZkzTBkg8Cp4IGYZzQBOqk5wPqPSneVxx1qxEuwdOe+KnlXaoKlWJGTjt7GgDHnhYjLADsDVCaAqSRzW3KjOeRVeWHj3+lAGDJ15BzVWUdq17m23ZIHzCsuZGXO7IoApSZ6Cq0vPNXHBqpKMk470AU5e9U5OlXJQcd8VUkHBoArPRQ9FAGgnQH2qRP1qIHtjtUqGgCwlWV9qqrirCHOKALkcZK9OTWrYwBcE8mqtlHyGY81ohgpJ9qALW1R060qD6VHG3IzU8Q3kdqAHomfxqQKfQipEQ4+U5p4BzyD+NAEJVSp67s9O2KrTKpUgDtVthgGqkh4I6GgDe8I63pfh7StRkuFu5tSuZoo0S0mEDxRIwkLb2jccusYwBn5T+OlrOoeH59J8Xtp2pQQnVLi2u7ezaKbepAZ5I87NvytIVBzg7SemM+eznEmQe1RhuO+e1AGroWqtpd2xaMXFpMvlXNuxKiaMkEjI5BBAKsOVYAjkV03irTRf2/8AbFhIZ5TH50sgAH2qLIUz4HSRSQsyjoxDj5ZBjhQTXR+ENdGn3AtbmZobSSTzEmCbzay4KiQL/EpUlXTo6MR1wQAZMVyejZNa2m3ZlJjBw3bNSeLdE+wTveWsQitncJLAr7xbSkbgob+KNlIeN/4kPqGAwon2uGFAHULM5ODwamDjByPxrKtrwMg4+arkdwpA+bAoAvRtgDHB61owTjBAJwBWOlyinkkkVKLuNSOevWgCLUUAkO3gHp7VBHJhOvPenXdwJfujGDVNXwxBxQBqLMCQRyc1I/zRsBjp3qjAScYNXIjhh+tAFNHaCTI79a0bSVJGzkbu9Qy26sNy9/Wo44DE2e1AG7bnkMOPrU7vkjnjrzWJHKVX5mNXYZxKANwyaAJbpRIMEYI7imMNkeATUxXavBHPvVeZX2EYBzxx2oAYt0oBBFTxXEbAY6j8KyJSRkcj61BHKY3LAn6UAbnzA5Udfepg6hQWIyKyobwOvJGR2qUTc8AY7UAW5ZW5OSB6VSkk8w46GleQ5qq0gUnP3qAJSwUYYc1A7Ap9PSoJ5+gUkk0xmKKAOD60ATwRiSUAHr/Kt2OXbFgZwOMVgWs6x53Z+bvVxLrgAHj19aALcj7snOMdqZvAByCc9ajEqE5yMUySeMfccUAPL9RjP40wwTX7Mokjt7SAB7i4kJEcQJwM45JJ4CjJY8AE1Z0ywe8eOSTzUtXk8pPKTfLO+M+XEvG5sckkhVHLFRzUet+II9OWO20wxi5hJKNC2+K0JXBKNj95MRkNMenSMKvJAJdVvrTw/amyitw0xIJtZwCSQQQ90OhIIytvkqpwXLMMDir27nvLmW4u5pJ7iUlnkdizMfUk1E7ksSSWJ6k1GoLttU8k9zigDt/B/iTTPDei+bJHdXOpy30cxS3nEBjjhwyBmaNwwZmOVH9wZPYv1y60EeE9bs9J1SBvO1eO9tbYxSq5hCOu3JTaCPMHUjIU+wPBEjHTk0FiBj9aAJlO5wAMVpxqFAAFZNqT5ue1asJ6GgCdcN97pTzz06U1OvAqXGFyOlAELDOfWqs3GeTnNXDGzDj5frVeQYz0PagCm65+tUbyENGc4zWk4CsCDmoJxu6DoMnigDmJVO8iqUwOM/hWzfQ4O4dTzise65JxQBRm7jOaqyjjj0qzNjPHFVZKAKzDiig4xRQB6/c/GzxBeXc1xLbKrzO0jCLV9VjQEnJ2ot2FUc8AAAdABTR8YtcP/LB//B5q/wD8mV5epyakXtQB6gvxe1s/8sJP/B5q/wD8mVPF8WdZdgDDLg/9RzV//kyvLlPGOat2h+egD1aL4maqy5Mc/wCGu6t/8mVKPiRqZP8Aq7n/AMHurf8AyXXnkByuO9WQeBQB3yfETU2/5Z3P/g91b/5LqxF4+1Fh86XWfQa9q3/yXXn6SY4H61NFISc56UAehDxze5wVvOfTXtV/+S6tDxhdtGWQXvHUf29qv/yXXAW8vOM1r6a6mXYx4bjmgDck8dXydFvP/B9qv/yXVWX4haivAjus++u6t/8AJdcxrTi0LswJUHoBk1zzX5lyEikHPVhigDvJPiZqauQIrjA9dd1b/wCS6T/hZmqdop//AAe6t/8AJlcCTn2oBGDQB3w+Jmq8fu5//B7q3/yZTx8StU/55z5/7Durf/Jdefjp71ID+BoA7dPHlz9ue9WycXjxiJrgazqokZASQpb7XkgEkgdOTVgfEfUyeI7j/wAHurf/ACXXBF+c54qSEjOcjigD0KP4g6g7YKXX/g+1X/5LqyvjXU5ANi3Sn/a13VT/AO3dcBAfmyAMVfjkPUHigDs4vFetvOMu4h7ga5q5Y/8Ak5xWlH4jv2ALfbRn017Vf/kuuJtZWZh6CtWBzwc5FAGxJ4tvo/vLe/X+3tV/+S6rSeNr9TgJef8Ag+1X/wCS6z7wYm6Ag9azrmMMvTp0oA6JPG14fvLe/wDg+1X/AOS6lTxndMM4vv8Awfar/wDJdcQ7bSRzTo2PrQB3Q8XXOTkX3/g+1X/5KqT/AISy4IGPt4J9df1X/wCSq4hJffn1qwk1AHWt4rusHb9uz2zr2q//ACVTE8W3rNyL3jr/AMT7Vf8A5LrmfNyPcU+JxycYoA69PE0xHP8AaAP/AGH9U/8AkqkPieYD/mIlvQa/qn/yVXLxOCeTzUjA/wAJ59qAOjbxNc7MqNQ/HX9V/wDkqov+EnvyuVF7n0Ovar/8l1irkRZbO2q5nAHp/SgDcfxZqCjO29/8H2q//JdMHjG94yt7yf8AoPar/wDJdYTSBjntTAyD05oA6EeMbw/w33/g+1X/AOS6D4vv+MLej669qv8A8l1zbzKM7dtVpZ8Y56UAdQ/jW8U9L0j/ALD2q/8AyXUX/Cc3xOFS8/8AB9qv/wAl1yTyjk5OTUtrHu+buaAOwXxhfsBhbzP/AGHdV/8Akul/4S3U8cJd/wDg+1X/AOS652H2PSrzbY1XKg5GaANRvFeqqP8AVXZPbGv6r/8AJdQv401FBzHeDH/Ue1X/AOS6wbiV43+hqtNMWO7HBPINAGvL4tb+0Vv2spDqCRmFbk6zqhkEZOSob7VnbnnGcUP8Q9TDYCXP467q3/yXXNT7GY8Y9KozAY3ZwRQB2P8AwsXUsE+XdY/7Durf/JdJ/wALF1PH+ruf/B7q3/yXXEFqM+vWgDtv+FjapjPl3H/g91b/AOS6aPiRqZJHl3OB/wBR3Vv/AJLricEHIYspPQ9qU8DHegDuo/iLqRcBkuce2u6t/wDJdWV8e356rd/+D7Vf/kuvOwcY9akiuSv3gfrQB6Mvjm9bHy3nP/Ue1X/5Lq4ni288sO4vgD0A17Vf/kuuF00rcMNhGM46VragyowQY+TjigDffxpdLn5b7/wfar/8lVAfG9+chBdZxn5te1Uf+3dclNJg5GeOlVJXyeT0oA6x/iFqC8+Xde//ABPdW/8Akumn4iakOkd0f+49q3/yXXFvICfmxUMhxyM/SgDsp/iVqifdiuPXnXdW/wDkusuf4tazGxAhl49dc1f/AOTK5qc5GSTWBff64+1AHdP8YdcX/lg3/g81f/5MqBvjPro6W7f+DzV//kyvO5emc1UkPXAoA9Qtfjl4htLqG4itUaSF1kUS6vqsiEg5G5GvCrD1BBB6EEUV5Q3IooAtgk8U8ZzUYp6/dHNAEymrVuwzkkVTQ+napUJ/CgDet5Pzq5vweKx7KQlQCelaKvz7UAThuamjbAxVZTzmpFxwRQBoxMcVraW3+kxA9M81gQufzrYsH2AtycCgCr4lkEt/Jt+4p4xWCchjk4rVv2MkhJArLmwG74NACA+/FAzxTRxxRnHGaAJBwaPwpm7mkDYPegCTdzU9scsR3qrmpYmKsDnjPNAGohAFSxSY71UZgDxTo3wenegDatHwOta1u+Apz+Fc/bOOMnrWra/6xB2zQBfvZAWHUc1Uds/lg0t1IC5U8gelRbuDmgCheKAcrnI6mq6yD8atzbS2BwSM1RuEKtlBlaALCyVIJRz/AJFUFfnrU8MgQqxUMAfunvQBeWX6CniTjORVHePTFSq+RxQBowyrnPX61cV8ngjFYfmnnBwaet+68YBx70AbMsmEwO9VZGzgYxVZbhnxk4HpTWfOaAJmbYvHXpVeSQ1HLL781AX9TzQBI8hB6VDJIDkng9qjkk45NQj95wD8386AJov3knOSB6VrQ4AHHQcVRt0CcA8etXVYAYFAE6nDAmrNxJjH04rP3bcc571PcOWjR+cGgCpeSc8mqfmc8U+5k+ckYwO1VJJdxPRR1wKAJJDk+1Vbg4ByakLDGMkCoLxiAFPfmgCvk9T9KFIzmo+c89qQN+VAE+eQKaSBTdwA96Td1oACec0Zz2oyCPalhUsy0AbPh5vIvYGJ+UsAQa2NXOL2bGAM8VjWamOYbhhh61pak/mMkh5Lrk0AZ0zncSeoFUi5MeTySMmpLlsEY61VkbI5/CgBCwx601jzSr0y3PpTHJwelAFe4Yj6YrCvXBfIPPetS8lCxn0FYczlmJJoArynjiq0mSeOlTynrVd+nvQBG3TNFIxJBooAsjrT1P0qPHNOA9sUATA/jUqkcD+lQr8tTLxjNAFq1fbIM1rJjHBrFXitizYNED3oAnU4A6U9DuPBOKiYYXPrTo2IxyMUAWYycjk8VqW8hWE5Gc8VkxdAelaEbfu+DQBXuW5zx1qjOu5c5q1OCWJ54qpI4Cc55oAiBxxntTJHIIPWo2kANRM5bjnFAE++nA/LwcVCOT1qQYzz6UATKcinA4PHSmIRjrThzjn8aANCNswqevY80IxDZGaiszuQj3qwBye1AFqKToccVtaXNvkXsAM1z6np279K1NPkKJI2f4cYoAtvJucknn2pokUfSq4lB3c1EZwDjtQA+4cA8cex70zcDgEc45qBpST2p3OMjvQA1oerR4I9O9MD446YqQHBwM0ZVydwGaAED45yPSpEbHTvUXlZzg04oygUATE89RUf8QAx60gzs9cmkXl8Y5oAvwnGfTFRyyg9/akyQnHXvVZjk0AOdsc9/aoiwx70rKxAoEOTlzx6UAQgPK+1fXGatRxBRhfx96TIUBQAKN2OmcetAEydeTxU+4cYz6VR3EN6j3qXzT3NAFnfj3qxJKPsQOQNp7VQMmQOPxpfOzHIgPUfhQBWlfrVdyN2cHFK3UjOaax4waAFQ8jmqt23mSn2q0ic59Kz5W/eHnvQAjU3nFLuwMHrTS3HrigBN3rTgw9Khb0700uQfagC2p75qxCuEJ9elUFkA4PQ1oW7BkwO1AF22JPfnFXLuTMcansKp2n+s6cVLesSQBjA7UAUpTVcnIzipn4B461Cx44/OgBEIKnOQQOOailIxgE460/rx271Bdv5cbHj2oAytQk3Nj0rLfrVuY7ie+aqykZ/SgCtJ1HQCoG+vNTSdD3qBz+dAEZ6Gig9KKALCckfzqQcZqNBhQD6VKvAzmgB6jNSouB04qNevHSploAev14rR0yQ79ue1Z46cVbs22TqT0oA1XXpxTF6irMg+XNVzx0oAkQ881oWzAg7vpWanHJq3C2cj3oAdPkNgHisu9bJwOMVp3HIyKxLh98h7UAQ9T1pRnjNPXhfWg4xQAqNkYqTr04zUQzmpAf0oAkXOeRmnbuzce1Ro2BS7txHfNAGlpv8QPpVvv75qjYnA5FWGbnrxQBYPHAPerUT4jPPJrOVufmNTLJlSAfagCS4mITA6k9qplyeppksvzdenFRs3HvQBKZG4waniumX73IqkDyMmnbspjA65oA01dWyynr+lIWI+lZ8blTkfQ+9XElGB6UAThicY7+9TKc8HtVYNjkVLG4U56j3oAnkGY8gUyIEsM9BUm790Op9KVeuePegCUKGPtTZAA3GMU5GO0+9Vpn60ADOOv6VEx5+XpRuz6Cms4U4HWgBevSiSeOLIzuJ6gdqqz3JyVTgdDiqxIIILAcZHufSgCw9ySTtGBSfaW4Aqqx96Tdg+1AGlBMXJUtj3qZD78nispZNpBFXo5PkyOtACyY9Bn2ph+9UbPjOPWmiQgFR1NAFxceWW545zWRKcsTjFaJcmPBPGKzXPNADOtIxpabjjmgBr9zTScY/Kp49vzblLZBC4OMH1qPbxz09qAI+Rnp7VbsmIkAzwepqvtwM45p9uxEi5oA6K0X5/pzUdwxLE9Md6s2q5j3ZBGKqTnJPXNAFZ2PQHPviq7ff4qY8kg0wDL9O9ADkVivPX0rK1OTLFAelbUpEcJYjNc1cSb3ZupzQBUk4FVpR3qy/41Xl6GgCnJ/OoWHrViTjgCq8mMcc0ARtj0oo75ooAsjt9KlWoVwT+FSDj60ATDFTKc1APeplFAEoPsKmQ4YH8agU/wCRUuaAOjgHm24IANV2Q9+vpT9JbdBt74qWZcA0AVwBjFTQ8Ng55qHbz1qWEfN3OKALE3EDN7dq5/PznvXQ3I/0NvSubzySetAD1NL+FMJ6elOzxyaAFHBpxOKYTk+1JuPegCXPp9aXqMdqjRulLuB59aANC3YKgwTjpVjf71nQycAdqsbs0AThgeKmVzjr3qqjcjipc0ARM25mJ9aAQCM9Kjk4YnNCkmgB9ODdKjyR60uaAJFPerER4FVQTip1bpQBaRssPSpicsBjjvVdOBnNKJBvNAF1n+6OwqVTx/OqqnGPfvU6sAtACiUqxz0P61FNkkk5AqORsH396YZfXJoAV2GPp3qFm6d6cWUjg1XkbByKAInIzx1700nkYpGOCaYWx+NAC5IPA4oz600t6flTC3p0oAkLcmrdtITH796z93PBqeB8JyO9AFknnqKbuwc55qLf+NIWzyetAFjfgbT3qrJyT0pzHsT+VQyv8woAUmlJBNRhvUZoBHY0ASd/agnmm596OpoAXPbrSKQsgwKSgYLDHrQB11n8tirYqhMwJJPH0rRj+XS0ABBrIlIJI7UARkA80sS/MMg460gGWA6YNWoQSRnGBxQBR1hyluBnGa51q1tclzMFxwKyW6ZoAhfHWq0tWWOarSdaAKstV3HJFWJeT7VXbgnmgCI8ZopW9cnFFAFlT0xUi9eelRD2qVD6UATDinr9ajFPU5NAEq8cdqkXqMVGo96kU84oA2tDf5yvqK0LpSDk1j6QxW5Arbuxg5oAo4yTzipIhyMnAqNuvSpYzluKALN6pFkcdMVyzcMSa6q8P+hjPpXMSj160AMViRUg7VCQQvWk39M0AWCRnqKYWphbnnqKQtnPFADg3v3oDHvTeBSFuc0AWY355qwjdDWerYxz+dWFY4oA0I2Jwe1SBqpJJg5FTLJnkUASSj5gR3qMH0p+8Ec03aDypoAM5pQCDyOO1AH0pcDrQAueOTj0qeJgBVTPHrQHx7dqALzTcYH0p8LY6/UVTU569KniPbPFAF1G4znirCkFM5qrGRwKk3cEZFADJnO4EnmoHfHSibrxVdm5460ASeZtOc/hTS4YHtUDHqe9RFxn2oAlkIyajZhgY603fzSck0AOY9v1phIBPrS4J4pm1h16UAO69OtWAdoHWq64Xr1pxbHrQBLuAH6UzfycVHv6+9NzjNAEzP2qGR8k4pGPX6VHQBIrGlz+dRcnrTgQKAJlPA9afuqvvPQUu/1oAmLYpIj+8XA5zUJap7Ib7hB796AOud9unquayXIJNaV3xbRqD0FZbAgECgB0Y5zzVuL5Imbjp1qtBGcjPerN+wjs/fFAHLag++4ds554qoT271JKdxJqEnmgBknSq0vep3PFV5D1FAFeTmqz9easOarsaAI24GfWig9MUUAWFHI7cVMhPOahXrUydKAJVx6VIoGfSox15qQc0APXipFI47HvUa9qkXrQBcsW23KHvnFdLNgwqT1Irlrc4lUjrmupX57RT3oAoNx2p8Q70jg885pYsEigC3d/8eNczJ6muouhmy4rln4oAic9cflTMECnnGKY3NAAKUUi/pT2xjnPSgBM89KQ9aO1NPqeKAAHGaejjPJ4qLpk0Z9etAFuNu9TK3eqCvjGeamWUUAXkbv+lPU8VTWUe9PEwNAFontSO4CjJquZeOmKaW5yeaAJs+tAPPtUBfPel3Y5oAuIR1zU8bDgVQEg4qWJ+eCcUAaavyeKlY7R2qmjEH+tSO4IoAbK/wA3Wqzvzg06V89TxVaRuoHegCQtkdKhY88UwvgdTTS+aAHbucfrTi2KhLHikL0AWd2Rz19qTJHTpUAcrjFL5oznmgB/mhXC4Yk+gpWfsTUXnDBzSFwelAEm4dTQW9KjDZxxyaXsD2oAcD+VHTmk6A46UA+tACgjmhc03ODSrQA49etJ25HPrStzmmnjigBQc/WtDTYx9tVQQwB6jvWei5YZJAra8PxD7UD6UAbt/GBsB9KzZAM8ZH0rS1Jsvx1AFZkvXA7UAS243SCovEMhW3K9M1ZtVw6461leInLShaAMJiTmojk9eKlNRN7UAQvz9KgfuKnfOCarycCgCu/GcVXY5+lWGxVd+nGKAI29qKGooAsJU6dKgQ9M9cVMvSgCZelSL2qJeCMVIDntQA9alTHWoVqVTzQBOnDAg11Nqd1kuRzXKpnNdNpjbrIjPagCGTOTzimxH5j606U4JxyaYg+b3oA0JsGzOOtctIPmYds9q6g/8ejCuYm/1rY9aAIiACe9NK9KeaT3oAbjj2ppNSN3PaonoAXPpSZ4pFOaG60AIKGB/GloPbNADTQDtPUUOM9KjY880AT785pysQOuaqhiO9SRvnpQBZVuMEDrTi4zUO7FGTQBMGxS7ucCoweMd6Og5oAmBxT1kx1quG56Um/r69qANHzyoFTCTcobNZZY5wTmpllIXFAFiRs/jVZ2O44+lMaQk8HmmF8k/WgCQn1phPPWms3emFs5oAeW45NN3445ph601m98UATF+eKRjk81CHz3o3E44oAmz608fpUK8k+1PDHP0oAkA75p5POBTAePelzzmgB38PFKOnHWmZoB56/WgBxp68AE9KiJHc0qnPagCTPoOaFG498UqL0Jpx6mgBVwOBzW94dTMpYjrxWGi4OOK6Pw+AISe9AFm+OZGYjnpVMgk8nrVu6OWJ/nVMYDHuKAL1muAWPUDmub1p990wzwDXSx/JbuT6VyN6+6dyT3oAqt0OOKiYcVKw9cionHr0oAgk645/CoJfappMnOM+1QOPzoAruOM1XYDvViQ4JxVZutADCetFITxRQBZWpkPSoF/CpUNAE45PFSDpyKjByR0qTvQA9eTxUi+lRqD61Ime1AEy8dcZroNDbdDtzz6Vzi1uaCeCBmgCxOuGI796SMDeOg96kuRhz0qJMbxnpQBeA3WpIrmbhdsz/XtXVR825z0xXM3i4uHz60AVWpq/lT2welM29wKAFPpUb46etSYxjOKjegCPGCe9Ozntj60hOQPWmHgjigCUHHWkI4pFb86Qk5PpQAE4H0pjYPWlbpz2oHXPegCNgePamjjODxUxAPWonXHXmgCVHDcc1ICaqqxU5PSpw2RQBNnvSE9qYDwcUEjPPWgBwfntRnmmA96O9ADy1S7uKrVJuOB7UABbnNKGBHvUW6gH1oAlJ96acEDmkzxmkPPHagB3tULtziiV8Dg01KAJF4zTlBPBpo5OOtPHWgB4xigHFNyOlB60ASjil4pgx2pRkde9AD6QcZzxSZC/WkOSaAHKMnirES+p5qOJe5FTgH5RQAp7UqjnmjPJIFA/CgB4Hpya6fRQEtuRgEVzSDJGa62wTZagY4xQBWnOc89+lQRqXYVLNnOe1RwjL8UAWLxhHZE98Vx8zbnb65rp9abZbFa5d8ZPrQA38ahk5NPx69aY/vQBC/rVeTvU7d8VA+ME5+ooArSYIqs3WrEnQ1WegBjfpRSN0ooAs98jrUsZ555qJSN3IqWMYHrQBMvB61KOlRL0qUfrQBIO3HNPUZ70xelPWgCRcYrX0NvnI55rIXjNaWkNicc80Aa90vLHNV4hucCrl0B1xVaLhxmgDTgQ+Ucnt0rmtQTE7Zrp4f9Wa53Vhi4zQBmn1pD2xTzTcYoAOO4qNlzn0qQnp6UxgRmgCFlx0qM8swxyKmY8UygCPPPpT+q8UjD5eDg+tR7iKAHHNAPSkLbj15p2eo7UADcDnFMx1zTuppoPXnpQAx0AFLE3ODSyc1F755oAtA4PtQx5qJGJ4PWnnrQAvakJ47UhPtSMevpQAuacGyKjz+NJuHrQA8dxS8+tR7sdaUGgCQE4oJ56UwH3prP2HWgBrNlj6daeoxgmmKOuaeSc8cUAS5Gc04enWogfSnB+mTigCQ9KT3NNycYpCcCgCUEA4o3GolOTUqLnrQAKNxqWMAU36U4daAJEcBtvOev0qdcHHNRxKATg4ycn3qQcdMe+aAHHpSgUgPTNPHT0oAltRulQHk56V10ChbbHtXL6cublPrmupYbYRkdqAM2cndgcGnWoyTnpTJc7iBU9qO/HFAGdr74AWsCTof51qa24afA5rKcZoAjbpxUbYzUjZqN+KAIHHWq7gc1YfNQS8c0AVJMfhVZ84qxIfeq5OKAGHrRSGigCyp54FTRg+1Qp1H0qVDgmgCdfepRx0qNDkCpM/yzQBKgwP6VKF6dajXlAe+cVIBxnJoAco59qu6a2LgY4z7VSj61asf9ev1oA6K4GUBzwarRZ3Hmrc/+p/CqsZ5NAGpan5SME8Vh6wMS5/St2w5yPasbWeWGR3oAxu3IpDxxUpUBQQOTUQ5HPpQAhyaYRxz1qQUx+uO1AELCozz+FSkdaYegoAiPHGaa3cGnMcdKYx+YUANOQcj8aUMRRnmmn6UAP3Gm9MnHWm0vSgBT3FN6+tO9KaOlACngZpVfIpuelA7UASZ9KRvegfWm0ABNNzzzSt3pg55oAkHP0pV96YBnBobgGgB7EdF60KO5FIo+XNL3oAdjJoHNMz1pwPAoAXoen5Up4x6UzccZp6YPWgBRz05pQnPNKOOgoHOc0AOXipBxUan5fepl/pQAoAwMU9Rz3poHFPj6j3oAmA4/wAKkUADkZpgG08VIKAAEk1IuCcd6jXnB96kDHpQBp6Mm64ye3et+6OFHr0ArI0BcuSfUVr3w5+gzQBnPyxz19qnQFYicYOKgPB4+tWZZXkgBdixVABnsB2oA5jUm3XLYNU2xjPepronzn571A/3sdqAI2GaibkVKRjNQvwaAImI6ZzVaWrEneqz9PpQBVmqs3WrE/U1XzzQAw96KSigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that both femoral heads are displaced laterally and superiorly. The acetabular index (AI) is also increased (&gt;40&deg;) bilaterally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14096=[""].join("\n");
var outline_f13_49_14096=null;
var title_f13_49_14097="Tilt table test PI";
var content_f13_49_14097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Tilt table test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a tilt table test, a doctor or nurse tilts your body at different angles. At the same time, he or she monitors your blood pressure and your heart's electrical activity. Your body's response to the changes in position can help your doctor or nurse figure out what, if anything, is wrong with your heart.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14097=[""].join("\n");
var outline_f13_49_14097=null;
var title_f13_49_14098="Calculator: Oxygenation index";
var content_f13_49_14098=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"OxygenIndex_form\" name=\"OxygenIndex_form\" onkeydown=\"clrResults();\" onkeyup=\"OxygenIndex_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Oxygenation index",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          OI = FiO2 * MeanAirwayPressure / PaO2",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              FiO2",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"FiO2_param\" onblur=\"OxygenIndex_fx(); minMaxCheck();\" onchange=\"OxygenIndex_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"FiO2_unit\" onchange=\"OxygenIndex_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|%O2\">",
"               %O2",
"              </option>",
"              <option value=\"100|0|fractionO2\">",
"               fractionO2",
"              </option>",
"              <option value=\"3|21|litresO2\">",
"               litresO2",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Mean Airway Pressure",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Mean_Airway_Pressure_param\" onblur=\"OxygenIndex_fx(); minMaxCheck();\" onchange=\"OxygenIndex_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Mean_Airway_Pressure_unit\" onchange=\"OxygenIndex_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0101971584453749|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"1033.22707947762|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"1019.71584453749|0|bar\">",
"               bar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"13.5950555825428|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"30.48|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"1|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"2.54|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"34.5315553878333|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"10.1971584453749|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"1.01971584453749|0|mbar\">",
"               mbar",
"              </option>",
"              <option value=\"1.35950555825428|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"70.3069601628334|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1.35950555825428|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              PaO2",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"PaO2_param\" onblur=\"OxygenIndex_fx(); minMaxCheck();\" onchange=\"OxygenIndex_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"PaO2_unit\" onchange=\"OxygenIndex_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              OI",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"OI_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"OI_unit\" onchange=\"OxygenIndex_fx();\" style=\"width:105px;\">",
"               <option value=\"1|0|#\">",
"                #",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|index\">",
"                index",
"               </option>",
"               <option value=\"1|0|none\">",
"                none",
"               </option>",
"               <option value=\"1|0|number\">",
"                number",
"               </option>",
"               <option value=\"1|0|points\">",
"                points",
"               </option>",
"               <option value=\"1|0|score\">",
"                score",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"OxygenIndex_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         Oxygenation Index Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          0-25 index:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Good outcome",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          25-40 index:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Chance of death &gt; 40%",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          40-1000 index:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Consider ECMO (extracorporeal membrane oxygenation)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The oxygenation index is used to assess the intensity of ventilatory support required to maintain oxygenation.",
"      </li>",
"      <li>",
"       It is used in neonatology and pediatrics to assess the need for potential ECMO therapy.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Brudno DS et at. Compliance, alveolar-arterial oxygen difference, and oxygenation index changes in patients managed with extracorporeal membrance oxygenation.",
"        <i>",
"         Ped. Pulmonology",
"        </i>",
"        . 9(1):19-23,1990.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Durand M et al. Oxygenation index in patients with meconium aspiration: conventional and extracorporeal membrane oxygention therapy.",
"        <i>",
"         Critical Care Med",
"        </i>",
"        . 18(4):373-7, 1990.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Perlman M (ed). Resident's Handbook of Neonatology, 2nd ed. (Hamilton, Ontario: BC Decker, 1999) p. 121.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        O'Brien A, Short B (ed.).",
"        <i>",
"         Children's National Medical Center ECMO Training Manual",
"        </i>",
"        . 8th ed (May, 1994) p. 19.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14098=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function OxygenIndex_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.OxygenIndex_form){",
"",
"",
"doCalc = true;",
"if (FiO2_param.value.indexOf(',') >= 0){ FiO2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(FiO2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = FiO2_unit.options[FiO2_unit.selectedIndex].value.split('|');",
"FiO2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Mean_Airway_Pressure_param.value.indexOf(',') >= 0){ Mean_Airway_Pressure_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Mean_Airway_Pressure_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Mean_Airway_Pressure_unit.options[Mean_Airway_Pressure_unit.selectedIndex].value.split('|');",
"Mean_Airway_Pressure = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (PaO2_param.value.indexOf(',') >= 0){ PaO2_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(PaO2_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = PaO2_unit.options[PaO2_unit.selectedIndex].value.split('|');",
"PaO2 = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"OI =  FiO2 * Mean_Airway_Pressure / PaO2;",
"",
"unit_parts = OI_unit.options[OI_unit.selectedIndex].value.split('|');",
"if (doCalc) OI_param.value = fixDP((OI - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if ((OI >= 0) && (OI <= 25)){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((OI >= 25) && (OI <= 40)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((OI >= 40) && (OI <= 1000)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.OxygenIndex_form){",
"",
"if (Mean_Airway_Pressure_param.value && Mean_Airway_Pressure < 0) {",
"Mean_Airway_Pressure = 0;",
"Mean_Airway_Pressure_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Mean Airway Pressure is 0 cmH2O.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Mean_Airway_Pressure_param.value && Mean_Airway_Pressure > 75) {",
"Mean_Airway_Pressure_param.value = \"\";",
"clrResults();",
"Mean_Airway_Pressure = 0;",
"doCalc = false;",
"alert(\"The maximum value for Mean Airway Pressure is 75 cmH2O.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (PaO2_param.value && PaO2 < 0) {",
"PaO2 = 0;",
"PaO2_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for PaO2 is 0 mmHg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (PaO2_param.value && PaO2 > 700) {",
"PaO2_param.value = \"\";",
"clrResults();",
"PaO2 = 0;",
"doCalc = false;",
"alert(\"The maximum value for PaO2 is 700 mmHg.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.OxygenIndex_form){",
"",
"OI_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f13_49_14098=null;
var title_f13_49_14099="Atypical nevi borders";
var content_f13_49_14099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical nevi borders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atypical nevus with irregular pigmentation and borders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14099=[""].join("\n");
var outline_f13_49_14099=null;
var title_f13_49_14100="Cycloserine: Patient drug information";
var content_f13_49_14100=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cycloserine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     see \"Cycloserine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/42/32419?source=see_link\">",
"     see \"Cycloserine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13264878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Seromycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701874",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cycloserine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11708 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14100=[""].join("\n");
var outline_f13_49_14100=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13264878\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015318\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015317\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015322\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015323\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015325\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015320\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015321\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015326\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015327\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=related_link\">",
"      Cycloserine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/42/32419?source=related_link\">",
"      Cycloserine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_49_14101="Complications of hemodialysis in the elderly patient";
var content_f13_49_14101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of hemodialysis in the elderly patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14101/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14101/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14101/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14101/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14101/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14101/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/49/14101/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients are subject to the same complications as all patients on maintenance hemodialysis. For a variety of reasons, many of these complications occur with increased frequency in elderly subjects. The most important are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intradialytic hypotension",
"     </li>",
"     <li>",
"      Malnutrition",
"     </li>",
"     <li>",
"      Withdrawal from dialysis",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues relating to these complications in the elderly are discussed in this topic review. General discussions of the complications among all patients undergoing hemodialysis are reviewed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HYPOTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension is the most frequent complication during dialysis. It occurs in 20 to 30 percent of dialysis treatments. An increased incidence rate of hypotension during dialysis is reported among elderly patients due to a variety of mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors contribute to episodic hypotension among all dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A rapid reduction in plasma osmolality, which causes extracellular water to move into the cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid fluid removal in an attempt to attain \"dry weight\" [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other factors such as autonomic neuropathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19684?source=see_link\">",
"       \"Autonomic dysfunction in dialysis patients\"",
"      </a>",
"      ); poor cardiac reserve; use of acetate rather than bicarbonate as a dialysate buffer; intake of antihypertensive medications that can impair cardiovascular stability; use of a lower sodium concentration in the dialysate; sudden release of adenosine during organ ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/4\">",
"       4",
"      </a>",
"      ]; and severe hypocalcemia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other factors may also contribute in selected patients: the ingestion of a meal immediately before or during dialysis, which can lead to postprandial hypotension (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/6\">",
"     6",
"    </a>",
"    ]; and increased synthesis of endogenous vasodilators such as nitric oxide&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors that can impair the normal response to volume removal are more prominent in elderly dialysis patients than in younger patients. These include autonomic dysfunction and limited cardiac reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/9\">",
"     9",
"    </a>",
"    ]; the former appears to be most significant among elderly patients with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most consistently described autonomic defect in dialysis patients resides in the",
"    <span class=\"nowrap\">",
"     baroreceptor/afferent",
"    </span>",
"    side of the autonomic loop. The impairment in baroreceptor function minimizes the reflex increase in circulating catecholamines that should be induced when hypotension occurs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19684?source=see_link\">",
"     \"Autonomic dysfunction in dialysis patients\"",
"    </a>",
"    .) When compared to younger patients, the elderly have an increased impairment of",
"    <span class=\"nowrap\">",
"     cardiopulmonary/pressor",
"    </span>",
"    receptor reflex function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/10\">",
"     10",
"    </a>",
"    ], especially in the presence of coexisting diabetes, left ventricular hypertrophy, severe congestive heart failure, or the ingestion of certain drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    . This autonomic defect can impair the patient's ability to maintain an adequate systemic blood pressure following a large degree of fluid removal via ultrafiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Limited cardiac reserve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restricted cardiac functional reserve among the elderly can reflect a number of pathologic conditions involving the myocardium, including left ventricular hypertrophy, and dilated, hypertrophic, and ischemic cardiomyopathies. The \"safety margin\" for blood pressure to decline during ultrafiltration is further reduced among older patients since the elderly have a lower average predialysis blood pressure, a finding that has been noted in most surveys.",
"   </p>",
"   <p>",
"    An increased incidence of postprandial hypotension also occurs among elderly patients, especially those with severe autonomic nervous system dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This results from an inability to increase cardiac output in response to the reduced total peripheral vascular resistance arising from elevated splanchnic blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/13\">",
"     13",
"    </a>",
"    ]. As a result, food ingestion during dialysis leads to a significant decline in systemic vascular resistance that can contribute to a fall in blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of possible interventions may reduce the frequency of intradialytic hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NUTRITIONAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of malnutrition among dialysis patients may be higher among the elderly than younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Malnutrition among all dialysis patients, including the elderly, is associated with decreased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of causes have been implicated in the development of malnutrition in elderly dialysis patients, including [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low income",
"     </li>",
"     <li>",
"      Social isolation",
"     </li>",
"     <li>",
"      Lack of understanding of basic nutritional requirements",
"     </li>",
"     <li>",
"      Malabsorption and gastrointestinal motility disorders",
"     </li>",
"     <li>",
"      Ill-fitting dentures",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Drug effects",
"     </li>",
"     <li>",
"      Impaired taste acuity",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Chronic constipation",
"     </li>",
"     <li>",
"      Frequent and prolonged hospitalizations",
"     </li>",
"     <li>",
"      Several dialytic and hormonal-metabolic factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Markers of malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The markers of malnutrition among dialysis patients include serum levels of albumin, transferrin, and prealbumin (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    ). Nonfluid weight loss remains a good predictor of insidious malnutrition. In addition, malnutrition suggested by a low serum albumin is also a harbinger of subsequent mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link&amp;anchor=H20#H20\">",
"     \"Patient survival and maintenance dialysis\", section on 'Malnutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DISCONTINUING DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Withdrawal from dialysis is a common cause of death among elderly patients with end-stage renal disease. The rate of voluntary withdrawal from dialysis increases with age. The decision to discontinue dialysis also correlates with the presence of certain significant comorbid conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elderly are at an increased risk for infections due in part to aging of the immune system and the effect of poor nutrition on overall immune function. Such infections result in significant morbidity and mortality among these patients.",
"   </p>",
"   <p>",
"    The most frequent life-threatening infections among elderly hemodialysis patients arise from infected vascular accesses. Sepsis due to gram negative organisms originating from the gastrointestinal or genitourinary tracts is the next most frequent source of serious infections in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elderly patients have an increased incidence of diverticulosis, angiodysplasia, and carcinoma. These lesions can contribute to a higher incidence of gastrointestinal (GI) bleeding when on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastritis is the most frequent cause of upper GI bleeding in all patients with end-stage renal disease, including the elderly. Hemorrhagic gastritis in elderly dialysis patients is due principally to the general effects of uremia and to therapy with nonsteroidal antiinflammatory drugs (NSAIDs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diverticulosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforation of colonic diverticulosis may complicate the clinical course of older patients with end-stage renal disease. The symptoms of perforation of the colon in elderly dialysis patients may be insidious, as signs of acute peritonitis do not commonly appear until late in the course of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, vague abdominal pain in the elderly patient with low-grade fever may be the only presenting symptom of perforation; such findings should not be ignored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Angiodysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiodysplasia (telangiectasia, arteriovenous malformation) is the second most common cause of gastrointestinal bleeding (which may be severe) in elderly patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14101/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PSYCHIATRIC ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dementia, delirium, and depression in dialysis patients, including the elderly, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11322?source=see_link\">",
"     \"Psychiatric illness in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1438801137\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autonomic dysfunction and limited cardiac reserve are prominent contributors to hypotension in elderly patients. Postprandial hypotension is more common in elderly patients, especially those with severe autonomic nervous system dysfunction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malnutrition may be higher among elderly patients and is associated with decreased survival. Causes include low income, social isolation, lack of understanding of basic nutritional requirements, malabsorption and gastrointestinal motility disorders, ill-fitting dentures, depression, drug effects, impaired taste acuity, and anorexia. The markers of malnutrition include serum levels of albumin, transferrin, and prealbumin. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nutritional considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Withdrawal from dialysis is a common cause of death among elderly patients and the rate of voluntary withdrawal increases with age. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Discontinuing dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The elderly are at an increased risk for infections. The most frequent life-threatening infections among elderly hemodialysis patients arise from infected vascular accesses followed by sepsis due to gram negative organisms originating from the gastrointestinal or genitourinary tracts. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elderly patients have an increased incidence of diverticulosis, angiodysplasia, and carcinoma. These lesions can contribute to a higher incidence of gastrointestinal (GI) bleeding when on dialysis. Gastritis is the most frequent cause of upper GI bleeding in all patients with end-stage renal disease, including the elderly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=see_link\">",
"       \"Gastrointestinal disease in dialysis patients\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Gastrointestinal bleeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18526147\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Nuhad Ismail, MD, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/1\">",
"      Letteri, JM. Symptomatic hypotension during hemodialysis. Semin Dial 1998; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/2\">",
"      Henrich WL. Hemodynamic instability during hemodialysis. Kidney Int 1986; 30:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/3\">",
"      Kouw PM, Kooman JP, Cheriex EC, et al. Assessment of postdialysis dry weight: a comparison of techniques. J Am Soc Nephrol 1993; 4:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/4\">",
"      Shinzato T, Miwa M, Nakai S, et al. Role of adenosine in dialysis-induced hypotension. J Am Soc Nephrol 1994; 4:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/5\">",
"      Ghent S, Judson MA, Rosansky SJ. Refractory hypotension associated with hypocalcemia and renal disease. Am J Kidney Dis 1994; 23:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/6\">",
"      Barakat MM, Nawab ZM, Yu AW, et al. Hemodynamic effects of intradialytic food ingestion and the effects of caffeine. J Am Soc Nephrol 1993; 3:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/7\">",
"      Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/8\">",
"      Yokokawa K, Mankus R, Saklayen MG, et al. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med 1995; 123:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/9\">",
"      Henrich WL. Dialysis considerations in the elderly patient. Am J Kidney Dis 1990; 16:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/10\">",
"      Cl&eacute;roux J, Giannattasio C, Grassi G, et al. Effects of ageing on the cardiopulmonary receptor reflex in normotensive humans. J Hypertens Suppl 1988; 6:S141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/11\">",
"      Lipsitz LA, Nyquist RP Jr, Wei JY, Rowe JW. Postprandial reduction in blood pressure in the elderly. N Engl J Med 1983; 309:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/12\">",
"      Sherman RA, Torres F, Cody RP. Postprandial blood pressure changes during hemodialysis. Am J Kidney Dis 1988; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/13\">",
"      Daugirdas JT. Dialysis hypotension: a hemodynamic analysis. Kidney Int 1991; 39:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/14\">",
"      Ross, C, Rutsky, EA. Dialysis modality selection in the elderly patient with end-stage renal disease: Advantages and disadvantages of peritoneal dialysis. Adv Perit Dial 1990; 6:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/15\">",
"      Canaud B, Tong L, Tentori F, et al. Clinical practices and outcomes in elderly hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2011; 6:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/16\">",
"      Chauveau P, Combe C, Laville M, et al. Factors influencing survival in hemodialysis patients aged older than 75 years: 2.5-year outcome study. Am J Kidney Dis 2001; 37:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/17\">",
"      Hakim RM, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis 1993; 21:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/18\">",
"      Chester AC, Rakowski TA, Argy WP Jr, et al. Hemodialysis in the eighth and ninth decades of life. Arch Intern Med 1979; 139:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14101/abstract/19\">",
"      Lipschutz DE, Easterling RE. Spontaneous perforation of the colon in chronic renal failure. Arch Intern Med 1973; 132:758.",
"     </a>",
"    </li>",
"    <li>",
"     Porush, JG, Faubert, PF. Chronic renal failure. In: Renal Disease in the Aged, Porush, JG, Faubert, PF (Eds), Little, Brown, Boston 1991, p. 285.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1872 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14101=[""].join("\n");
var outline_f13_49_14101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1438801137\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HYPOTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Limited cardiac reserve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NUTRITIONAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Markers of malnutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DISCONTINUING DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GASTROINTESTINAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diverticulosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Angiodysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PSYCHIATRIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1438801137\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18526147\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19684?source=related_link\">",
"      Autonomic dysfunction in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=related_link\">",
"      Gastrointestinal disease in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/3/11322?source=related_link\">",
"      Psychiatric illness in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_49_14102="Mastectomy incisions for inner quadrant tumors";
var content_f13_49_14102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mastectomy incisions for tumors of the inner quadrants of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 614px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Design of the obliquely placed modi���������ed Stewart incision for cancer of the inner quadrant of the breast. The medial extent of the incision often must incorporate skin to the midsternum to allow a 1 to 2 cm margin in all directions from the edge of the tumor. Lateral extent of the incision ends at the anterior margin of the latissimus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14102=[""].join("\n");
var outline_f13_49_14102=null;
var title_f13_49_14103="Epidemiology, microbiology and pathogenesis of Acinetobacter infection";
var content_f13_49_14103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, microbiology and pathogenesis of Acinetobacter infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14103/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14103/contributors\">",
"     Zeina A Kanafani, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14103/contributors\">",
"     Souha S Kanj, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14103/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14103/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14103/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14103/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/49/14103/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter is a gram-negative coccobacillus that has emerged from an organism of questionable pathogenicity to an infectious agent of importance to hospitals worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/1\">",
"     1",
"    </a>",
"    ]. The organism has the ability to accumulate diverse mechanisms of resistance, leading to the emergence of strains that are resistant to all commercially available antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology, pathogenesis, and epidemiology of Acinetobacter infection will be reviewed here. The clinical manifestations, treatment, and prevention of Acinetobacter infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link\">",
"     \"Treatment and prevention of Acinetobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of Acinetobacter infections is broad and includes infection associated with tropical environments, wars and natural disasters, and hospital outbreaks in temperate climates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. It naturally inhabits water and soil, and has also been isolated from foods and arthropods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. In humans, Acinetobacter can colonize skin, wounds, and the respiratory and gastrointestinal tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/10\">",
"     10",
"    </a>",
"    ]. Some strains can survive environmental desiccation for weeks, a characteristic that promotes transmission through fomite contamination in hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, Acinetobacter has been a pathogen of humid climates. Years before Acinetobacter became a concern in ICUs in the United States, it was cited as the cause of 17 percent of cases of ventilator-associated pneumonias in a Guatemalan ICU &ndash; second only to Pseudomonas, which caused 19 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the 1970s, Acinetobacter infections have become an increasingly common nosocomial problem in temperate climates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/15\">",
"     15",
"    </a>",
"    ]. Their emergence is likely related in part to their survival ability and their rapid development of resistance to the major antibiotic classes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial Acinetobacter infections have been observed more frequently in the summer than in other seasons; in one review of 3447 Acinetobacter infections reported to the Centers for Disease Control (CDC) between 1987 and 1996, infection rates were approximately 50 percent higher from July to October than at other times of the year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/17\">",
"     17",
"    </a>",
"    ]. Possible explanations include more humid ambient air (which favors growth of Acinetobacter in its natural habitats), and potentially preventable environmental contaminants such as condensate from air-conditioning units, which has been implicated as a cause of epidemic Acinetobacter infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Health care-associated infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most information about health care-associated Acinetobacter infections is based on data from outbreak investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/14\">",
"     14",
"    </a>",
"    ]. Infections with A. baumannii tend to occur in debilitated patients in ICUs (among both children and adults) and among residents of long-term care facilities (particularly facilities caring for ventilator-dependent patients). Additional risk factors include recent surgery, central vascular catheterization, tracheostomy, mechanical ventilation, enteral feeding, and treatment with third generation cephalosporin, fluoroquinolone, or carbapenem antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/1,18-20\">",
"     1,18-20",
"    </a>",
"    ]. Risk factors among neonates include low birth weight,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    , and central venous catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acinetobacter outbreaks have been traced to common-source contamination (particularly contaminated respiratory and ventilator equipment), and to cross-infection by the hands of health care workers caring for colonized or infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/14,23,24\">",
"     14,23,24",
"    </a>",
"    ]. Once Acinetobacter is introduced into a hospital, serial or overlapping outbreaks caused by various multidrug-resistant strains are frequently observed. Subsequently, endemicity of multiple strains is established, with a single endemic strain predominating at any one time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/14\">",
"     14",
"    </a>",
"    ]. Prolonged colonization may contribute to the endemicity of A. baumannii after an outbreak; in one study, colonization persisted for up to 42 months and affected 17 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dramatic multihospital outbreaks have been described in the United States, Europe, South America, Africa, Asia, and the Middle East [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/2,19,26,27\">",
"     2,19,26,27",
"    </a>",
"    ]. As an example, a monoclonal outbreak of a carbapenemase producing (OXA-40) Acinetobacter was described in the greater Chicago area in 2005; subsequently, at least five hospitals, three long-term care facilities, and more than 200 patients were affected by this outbreak [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of monoclonal outbreaks in multiple hospitals suggests spread between institutions, presumably by movements of patients or personnel, or by exposure to common-source contamination of food or equipment. Such outbreaks highlight the importance of ongoing surveillance and measures to prevent the introduction of Acinetobacter into, and spread from, long term care facilities.",
"   </p>",
"   <p>",
"    Data regarding the prognosis of patients with Acinetobacter infections are limited. While such patients usually have high mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/28\">",
"     28",
"    </a>",
"    ], it is unclear whether mortality can be attributed to Acinetobacter infection. In a matched cohort study of trauma patients, the effect of Acinetobacter infections on mortality was inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/29\">",
"     29",
"    </a>",
"    ]. Cases had a longer stay in the intensive care unit and a higher rate of organ failure than control patients with infections other than Acinetobacter. Risk factors for mortality in patients with Acinetobacter infections include imipenem resistance, intensive care unit stay, female gender, old age, pneumonia, diabetes mellitus, and septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Community-acquired infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community acquired Acinetobacter infection has been reported in Australia and Asia; in Australia, community-acquired pneumonia occurs more frequently during the wet (monsoon) season [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ]. In tropical northern Australia, A. baumannii accounts for 10 percent of cases of severe community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Community-acquired infections have been characterized by pharyngeal carriage of the organism, aggressive pneumonia, and high case fatality rates. Risk factors include tobacco use, chronic obstructive pulmonary disease, diabetes, alcoholism, and cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/3,4,32\">",
"     3,4,32",
"    </a>",
"    ]. Community-acquired bloodstream infections have also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/4,33\">",
"     4,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, community-acquired infections are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/34\">",
"     34",
"    </a>",
"    ]. The reason for the higher prevalence of Acinetobacter infections in certain geographic areas is not known, but it may be due in part to differences in temperature and humidity that influence colonizing bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Wars and natural disasters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wartime Acinetobacter infections have been reported in the Korean war, the Vietnam war, and the wars in Iraq and Afghanistan [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Between January 2002 and August 2004, A. baumannii bloodstream infections were identified among 85 soldiers in military hospitals injured in Afghanistan and Iraq. A total of 35 percent of the isolates were susceptible only to imipenem, and 4 percent showed resistance to all standard drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/35\">",
"     35",
"    </a>",
"    ]. According to another report, among 142 Acinetobacter isolates recovered from October 2003 to November 2005, isolates from military personnel had a lower rate of susceptibility to imipenem than isolates from nondeployed personnel (63 versus 87 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The heteroclonality and reappearance of Acinetobacter in personnel participating in several military operations over several decades suggests multiple sources, including local foods, battlefield wound contamination, and environmental spread and cross-infection in field and referral hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/36,40,41\">",
"     36,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acinetobacter should also be included in the differential diagnosis of soft tissue infections after exposure to a tropical environment. Among 17 patients evacuated in critical condition due to soft tissue injuries and fractures after the Southeast Asia tsunami in 2004, multi-drug resistant Acinetobacter was isolated from 20 percent of wounds, as well as from blood and respiratory secretions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/42\">",
"     42",
"    </a>",
"    ]. Following the 1999 Marmara earthquake in Turkey, A. baumannii was the most prevalent nosocomial pathogen in a Turkish ICU, where it had only rarely been isolated previously [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3964680\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acinetobacter is easily isolated in standard cultures, although identification can be delayed since it is relatively nonreactive in many biochemical tests commonly used to differentiate among gram-negative bacilli. Acinetobacter species appear as short, broad gram-negative rods in the rapid growth phase but assume a more coccobacillary shape in the stationary phase. They are indole-negative and do not ferment glucose or reduce nitrate.",
"   </p>",
"   <p>",
"    The genus Acinetobacter initially encompassed a heterogeneous collection of non-pigmented, oxidase-positive and oxidase-negative gram-negative rods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. It currently comprises gram-negative coccobacilli that are non-motile, strictly aerobic, catalase-positive, and oxidase-negative [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 30 different species belonging to the genus Acinetobacter have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Most of these species are environmental organisms and have not been associated with human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/49\">",
"     49",
"    </a>",
"    ]. A. baumannii, A. calcoaceticus and A. lwoffi are the species most frequently reported in the clinical literature. The term A. calcoaceticus-A. baumannii complex (ACB) is sometimes used since it is difficult to differentiate among Acinetobacter species on the basis of phenotypic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/50\">",
"     50",
"    </a>",
"    ]. The ACB is compromised of genospecies 1 (A. calcoaceticus), genospecies 2 (A. baumannii), genospecies 3, and genospecies 13TU [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. More recently, A. junii has been described as an opportunistic pathogen in the setting of prior antimicrobial therapy, invasive procedures, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acinetobacter baumannii (genospecies 2 of the ACB complex) is the most resistant of the genospecies and has the greatest clinical importance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/55\">",
"     55",
"    </a>",
"    ]. This pathogen is the most frequently isolated species (&gt;90 percent of Acinetobacter spp isolates) and is typically associated with outbreaks in the hospital setting. It is characterized by its resistance to harsh environment factors, a property that enables such organisms to spread rapidly and develop resistance to all conventional antimicrobials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/48,56\">",
"     48,56",
"    </a>",
"    ]. Other species that have been associated with disease include A. johnsonii, A. lwoffi, and A. calcoaceticus subsp anitratus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3964687\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors contribute to Acinetobacter virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The organism can survive under dry [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/11\">",
"       11",
"      </a>",
"      ] and iron-deficient conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately one-third of strains produce a polysaccharide capsule that works with the cell wall liposaccharide to prevent complement activation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/60\">",
"       60",
"      </a>",
"      ]. The capsule may also delay phagocytosis.",
"     </li>",
"     <li>",
"      Colonization in the lung is facilitated by the ability of Acinetobacter species to adhere to human bronchial epithelial cells using fimbriae [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/61\">",
"       61",
"      </a>",
"      ]. In addition, colonization of environmental surfaces is promoted by adhesion via pili and the subsequent formation of biofilms [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14103/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214775\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acinetobacter is a gram-negative coccobacillus that has emerged from an organism of questionable pathogenicity to an infectious agent of importance to hospitals worldwide. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The epidemiology of Acinetobacter infections is broad and includes infection associated with tropical environments, wars and natural disasters, and hospital outbreaks in temperate climates. Some strains can survive environmental desiccation for weeks, a characteristic that promotes transmission through fomite contamination in hospitals. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In humans, Acinetobacter can colonize skin, wounds, and the respiratory and gastrointestinal tracts. Nosocomial infections tend to occur in debilitated patients in intensive care units (among both children and adults) and among residents of long-term care facilities (particularly facilities caring for ventilator-dependent patients). Additional risk factors include recent surgery, central vascular catheterization, tracheostomy, mechanical ventilation, enteral feedings, and treatment with third generation cephalosporin, fluoroquinolone, or carbapenem antibiotics. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Health care-associated infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Community-acquired Acinetobacter infection has been reported in Australia and Asia; in Australia, community-acquired pneumonia occurs more frequently during the wet (monsoon) season. These infections are associated with aggressive pneumonia and high case fatality rates. Risk factors include tobacco use, chronic obstructive pulmonary disease, diabetes, alcoholism, and cancer. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Community-acquired infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wartime Acinetobacter infections have been reported in the Korean war, the Vietnam war, and the wars in Iraq and Afghanistan. Acinetobacter infections have also been associated with natural disasters including tsunamis and earthquakes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Wars and natural disasters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acinetobacter is easily isolated in standard cultures, although identification can be delayed since it is relatively nonreactive in many biochemical tests commonly used to differentiate among gram-negative bacilli. Acinetobacter species appear as short, broad gram-negative rods in the rapid growth phase but assume a more coccobacillary shape in the stationary phase. (See",
"      <a class=\"local\" href=\"#H3964680\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acinetobacter baumannii (genospecies 2 of the ACB complex) is the most resistant of the genospecies and has the greatest clinical importance. This pathogen is the most frequently isolated species (&gt;90 percent of Acinetobacter spp isolates) and is typically associated with outbreaks in the hospital setting. (See",
"      <a class=\"local\" href=\"#H3964680\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/1\">",
"      Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/2\">",
"      Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50:2941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/3\">",
"      Leung WS, Chu CM, Tsang KY, et al. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006; 129:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/4\">",
"      Anstey NM, Currie BJ, Hassell M, et al. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol 2002; 40:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/5\">",
"      Houang ET, Chu YW, Leung CM, et al. Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J Clin Microbiol 2001; 39:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/6\">",
"      Chen MZ, Hsueh PR, Lee LN, et al. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001; 120:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/7\">",
"      Berg DE, Hershow RC, Ramirez CA, Weinstein RA. Control of nosocomial infections in an intensive care unit in Guatemala City. Clin Infect Dis 1995; 21:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/8\">",
"      Ash RJ, Mauck B, Morgan M. Antibiotic resistance of gram-negative bacteria in rivers, United States. Emerg Infect Dis 2002; 8:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/9\">",
"      La Scola B, Fournier PE, Brouqui P, Raoult D. Detection and culture of Bartonella quintana, Serratia marcescens, and Acinetobacter spp. from decontaminated human body lice. J Clin Microbiol 2001; 39:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/10\">",
"      Albrecht MC, Albrecht MA, Griffith ME, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006; 203:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/11\">",
"      Wendt C, Dietze B, Dietz E, R&uuml;den H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997; 35:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/12\">",
"      Bernards AT, Harinck HI, Dijkshoorn L, et al. Persistent Acinetobacter baumannii? Look inside your medical equipment. Infect Control Hosp Epidemiol 2004; 25:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/13\">",
"      Getchell-White SI, Donowitz LG, Gr&ouml;schel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol 1989; 10:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/14\">",
"      Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/15\">",
"      Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009; 73:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/16\">",
"      Towner KJ. Clinical importance and antibiotic resistance of Acinetobacter spp. Proceedings of a symposium held on 4-5 November 1996 at Eilat, Israel. J Med Microbiol 1997; 46:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/17\">",
"      McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial Infections Surveillance System. Clin Infect Dis 1999; 29:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/18\">",
"      Villers D, Espaze E, Coste-Burel M, et al. Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 1998; 129:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/19\">",
"      Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/20\">",
"      Garnacho-Montero J, Ortiz-Leyba C, Fern&aacute;ndez-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005; 31:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/21\">",
"      Mittal N, Nair D, Gupta N, et al. Outbreak of Acinetobacter spp septicemia in a neonatal ICU. Southeast Asian J Trop Med Public Health 2003; 34:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/22\">",
"      Huang YC, Su LH, Wu TL, et al. Outbreak of Acinetobacter baumannii bacteremia in a neonatal intensive care unit: clinical implications and genotyping analysis. Pediatr Infect Dis J 2002; 21:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/23\">",
"      Hartstein AI, Rashad AL, Liebler JM, et al. Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags. Am J Med 1988; 85:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/24\">",
"      Maragakis LL, Cosgrove SE, Song X, et al. An outbreak of multidrug-resistant Acinetobacter baumannii associated with pulsatile lavage wound treatment. JAMA 2004; 292:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/25\">",
"      Marchaim D, Navon-Venezia S, Schwartz D, et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol 2007; 45:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/26\">",
"      Naas T, Coignard B, Carbonne A, et al. VEB-1 Extended-spectrum beta-lactamase-producing Acinetobacter baumannii, France. Emerg Infect Dis 2006; 12:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/27\">",
"      Coelho JM, Turton JF, Kaufmann ME, et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44:3623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/28\">",
"      Siempos II, Vardakas KZ, Kyriakopoulos CE, et al. Predictors of mortality in adult patients with ventilator-associated pneumonia: a meta-analysis. Shock 2010; 33:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/29\">",
"      Eberle BM, Schn&uuml;riger B, Putty B, et al. The impact of Acinetobacter baumannii infections on outcome in trauma patients: a matched cohort study. Crit Care Med 2010; 38:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/30\">",
"      Dizbay M, Tunccan OG, Sezer BE, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors. Scand J Infect Dis 2010; 42:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/31\">",
"      Metan G, Sariguzel F, Sumerkan B. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009; 20:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/32\">",
"      Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin Infect Dis 1992; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/33\">",
"      Wang JT, McDonald LC, Chang SC, Ho M. Community-acquired Acinetobacter baumannii bacteremia in adult patients in Taiwan. J Clin Microbiol 2002; 40:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/34\">",
"      Cordes LG, Brink EW, Checko PJ, et al. A cluster of Acinetobacter Pneumonia in foundry workers. Ann Intern Med 1981; 95:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep 2004; 53:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/36\">",
"      Scott P, Deye G, Srinivasan A, et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 2007; 44:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/37\">",
"      LINDBERG RB, WETZLER TF, MARSHALL JD, et al. The bacterial flora of battle wounds at the time of primary debridement; a study of the Korean battle casualty. Ann Surg 1955; 141:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/38\">",
"      Murray CK, Yun HC, Griffith ME, et al. Acinetobacter infection: what was the true impact during the Vietnam conflict? Clin Infect Dis 2006; 43:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/39\">",
"      Hawley JS, Murray CK, Griffith ME, et al. Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 2007; 51:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/40\">",
"      Griffith ME, Lazarus DR, Mann PB, et al. Acinetobacter skin carriage among US army soldiers deployed in Iraq. Infect Control Hosp Epidemiol 2007; 28:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/41\">",
"      Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006; 50:4114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/42\">",
"      Maegele M, Gregor S, Steinhausen E, et al. The long-distance tertiary air transfer and care of tsunami victims: injury pattern and microbiological and psychological aspects. Crit Care Med 2005; 33:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/43\">",
"      Onc&uuml;l O, Keskin O, Acar HV, et al. Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect 2002; 51:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/44\">",
"      BRISOU J, PREVOT AR. [Studies on bacterial taxonomy. X. The revision of species under Acromobacter group]. Ann Inst Pasteur (Paris) 1954; 86:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/45\">",
"      Ingram M, Shewan JW. Introductory reflections on the Pseudomonas-Achromobacter group. J Appl Bacteriol 1960; 23:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/46\">",
"      Juni E. Interspecies transformation of Acinetobacter: genetic evidence for a ubiquitous genus. J Bacteriol 1972; 112:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/47\">",
"      Dijkshoorn L, van der Toorn J. Acinetobacter species: which do we mean? Clin Infect Dis 1992; 15:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/48\">",
"      Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010; 23:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/49\">",
"      Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010; 35:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/50\">",
"      Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/51\">",
"      Zarrilli R, Giannouli M, Tomasone F, et al. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries 2009; 3:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/52\">",
"      Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/53\">",
"      Gerner-Smidt P, Tjernberg I, Ursing J. Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol 1991; 29:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/54\">",
"      Hung YT, Lee YT, Huang LJ, et al. Clinical characteristics of patients with Acinetobacter junii infection. J Microbiol Immunol Infect 2009; 42:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/55\">",
"      Chuang YC, Sheng WH, Li SY, et al. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011; 52:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/56\">",
"      Seifert H, Baginski R, Schulze A, Pulverer G. The distribution of Acinetobacter species in clinical culture materials. Zentralbl Bakteriol 1993; 279:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/57\">",
"      Juni E. Genetics and physiology of Acinetobacter. Annu Rev Microbiol 1978; 32:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/58\">",
"      Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005; 11:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/59\">",
"      Goel VK, Kapil A. Monoclonal antibodies against the iron regulated outer membrane Proteins of Acinetobacter baumannii are bactericidal. BMC Microbiol 2001; 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/60\">",
"      Kaplan N, Rosenberg E, Jann B, Jann K. Structural studies of the capsular polysaccharide of Acinetobacter calcoaceticus BD4. Eur J Biochem 1985; 152:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/61\">",
"      Lee JC, Koerten H, van den Broek P, et al. Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol 2006; 157:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14103/abstract/62\">",
"      Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology 2003; 149:3473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3121 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14103=[""].join("\n");
var outline_f13_49_14103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1214775\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Health care-associated infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Community-acquired infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Wars and natural disasters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3964680\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3964687\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1214775\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=related_link\">",
"      Treatment and prevention of Acinetobacter infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_49_14104="Initial evaluation of shock in children";
var content_f13_49_14104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation of shock in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14104/contributors\">",
"     Mark Waltzman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14104/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14104/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14104/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/49/14104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a dynamic and unstable pathophysiologic state characterized by inadequate tissue perfusion. Shock develops as the result of conditions that cause decreased intravascular volume, abnormal distribution of intravascular volume,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired cardiovascular function. Aggressive treatment within the first few hours after presentation may prevent the invariable progression and poor outcome that characterize the natural clinical course of shock, manifested clinically by end-organ damage, failure of multiple organ systems, and death.",
"   </p>",
"   <p>",
"    Children can effectively compensate for circulatory dysfunction (primarily by increasing heart rate, systemic vascular resistance, and venous tone), maintaining normal blood pressures despite significantly compromised tissue perfusion. Consequently, hypotension is a very late and ominous finding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The challenge for the clinician is to recognize children in shock early (before they develop hypotension), when they are more likely to respond favorably to treatment.",
"   </p>",
"   <p>",
"    Although the cause of shock may not be initially apparent, treatment must begin immediately. A systematic approach to the evaluation of children with evidence of poor perfusion typically identifies features of the history, physical examination, and ancillary studies that suggest the etiology of the underlying condition (",
"    <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the initial evaluation of children with shock. The initial management of shock and the evaluation and management of specific types of pediatric shock are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"       \"Initial management of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience suggests that frequent causes of shock among children include hypovolemia from diarrheal disease or traumatic hemorrhage and sepsis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common cause of pediatric shock worldwide is likely hypovolemia from diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/3\">",
"       3",
"      </a>",
"      ]. Widespread use of oral rehydration therapy has substantially reduced mortality, although this intervention continues to be underutilized in some developed countries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link&amp;anchor=H4#H4\">",
"       \"Oral rehydration therapy\", section on 'Efficacy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trauma, including hemorrhagic shock, is also a significant cause of death in children [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe sepsis also occurs frequently in children around the world, especially low birth weight newborns and infants under one month of age, immunosuppressed patients, and children with chronic debilitating disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H2332152#H2332152\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a state of circulatory dysfunction that develops when tissue perfusion does not effectively deliver oxygen to cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link\">",
"     \"Physiology and classification of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shock can develop from a variety of conditions that result in the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insufficient circulating blood volume (preload)",
"     </li>",
"     <li>",
"      Changes in vascular resistance (afterload)",
"     </li>",
"     <li>",
"      Heart failure (contractility)",
"     </li>",
"     <li>",
"      Obstruction to blood flow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiologic consequences of inadequate circulation may be compounded by conditions (such as fever from infection or increased work of breathing from injury) that increase tissue metabolic needs.",
"   </p>",
"   <p>",
"    Deleterious effects of decreased tissue perfusion include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor perfusion of vital organs results in impaired function. For example, inadequate perfusion of the brain and kidneys can cause depressed mental status and low urine output, respectively.",
"     </li>",
"     <li>",
"      Lactic acid accumulates as cells switch to anaerobic metabolism to generate energy. Increased lactic acid in tissues causes metabolic acidosis, which interferes with cell and organ function.",
"     </li>",
"     <li>",
"      Hypoperfusion initiates inflammatory events (such as the activation of neutrophils and release of cytokines) that disrupt the microcirculation and contribute to tissue injury. Adrenergic stress responses that are activated to compensate for decreased tissue perfusion and increased metabolic demand include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood flow to vital organs is preserved through stimulation of the heart (tachycardia and increased contractility) by the sympathetic nervous system and increased peripheral vasoconstriction (increased systemic vascular resistance and venous tone) mediated by the sympathetic nervous and renin-angiotensin systems.",
"     </li>",
"     <li>",
"      Hormones such as catecholamines, corticosteroids, and glucagon initiate increased liver glycolysis and lipolysis to maintain cell energy sources, causing an increase in lactic acid production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classification of shock is based upon the physiologic mechanisms that result in decreased tissue perfusion (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ). This classification has important consequences for management decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For any given condition that can cause shock, the classification may be mixed. Patients with distributive shock, in particular, often have multiple physiologic abnormalities. As an example, children with distributive shock from sepsis may also have volume loss (from vomiting, diarrhea, poor intake, or increased insensible fluid loss from tachypnea and fever) and myocardial depression from the effect of inflammatory mediators released in response to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Clinical classification of shock'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypovolemic shock",
"      </strong>",
"      &ndash; Hypovolemic shock is the most common type of shock in children. Causes include fluid and electrolyte loss (as from gastroenteritis or osmotic diuresis), hemorrhage (as from trauma), capillary leak (as from bowel obstruction or burns), inadequate fluid intake, and insensible losses (eg, fever, tachypnea, or burns). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H2#H2\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Etiology'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      By definition, preload is decreased in hypovolemic shock. Systemic vascular resistance may be increased as the result of compensatory mechanisms. Cardiac contractility is typically normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H3#H3\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Pathophysiology and classification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Distributive shock",
"      </strong>",
"      &ndash; Distributive shock may occur as the result of sepsis, anaphylaxis, or neurologic injury. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H9#H9\">",
"       \"Physiology and classification of shock in children\", section on 'Distributive shock'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      With sepsis and anaphylaxis, volume depletion may develop because of losses related to the underlying infection (septic shock), or inflammatory cascade (anaphylaxis). Both processes are associated with increased capillary permeability with loss of plasma from the intravascular space into the tissues. Myocardial dysfunction can also contribute to poor tissue perfusion.",
"      <br/>",
"      <br/>",
"      In distributive shock, abnormal distribution of blood flow as the result of changes in vasomotor tone causes inappropriate tissue perfusion (such as decreased splanchnic circulation with increased flow to skin and muscle). Systemic vascular resistance (SVR) may be low, producing increased blood flow to skin and a wide pulse pressure (warm shock) or SVR may be increased, in which case, blood flow to skin is decreased and the pulse pressure is narrow (cold shock). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H13#H13\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Neurogenic shock may develop in a child with a high spinal cord injury (above the sixth thoracic spinal level) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/2\">",
"       2",
"      </a>",
"      ]. Uncontrolled vasodilation occurs as the result of the sudden loss of sympathetic tone. Compensatory sympathetic mechanisms (such as tachycardia and peripheral vasoconstriction) are absent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiogenic shock",
"      </strong>",
"      &ndash; Cardiogenic shock results from pump failure either because of intrinsic cardiac disease (such as congenital heart disease, myocarditis, trauma, or arrhythmia) or obstruction of blood flow (such as tension pneumothorax or massive pulmonary embolism), or both (as with cardiac tamponade or ductal-dependent congenital abnormalities) (",
"      <a class=\"graphic graphic_table graphicRef67841 \" href=\"UTD.htm?37/34/38445\">",
"       table 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Physiologic features of cardiogenic shock include tachycardia, increased systemic vascular resistance, and decreased cardiac output [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/2\">",
"       2",
"      </a>",
"      ]. Conditions that cause obstructive shock must be recognized quickly because they generally require specific treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H10#H10\">",
"       \"Physiology and classification of shock in children\", section on 'Cardiogenic shock'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the initial evaluation of shock in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediate identification of life-threatening conditions",
"     </li>",
"     <li>",
"      Rapid recognition of circulatory compromise",
"     </li>",
"     <li>",
"      Early classification of the type and cause of shock",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with life-threatening conditions, hypotension, and compensated shock (eg, poor perfusion with a normal blood pressure) should be recognized from an initial rapid assessment of appearance, breathing, and circulation. The type and cause of shock can generally be determined from a focused history, thorough physical examination, and selected diagnostic studies (",
"    <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A general approach to the assessment of airway, ventilatory, and circulatory function in children is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link\">",
"     \"Assessment of perfusion in pediatric resuscitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This discussion will focus on the clinical features that identify and classify shock and can be used to evaluate response to treatment.",
"   </p>",
"   <p>",
"    The initial management of undifferentiated shock is provided in the algorithm and discussed in detail separately (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rapid assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pediatric assessment triangle (PAT) provides a quick evaluation of appearance, breathing, and circulation for acutely ill or injured children that should identify conditions that require immediate intervention. The PAT is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Pediatric assessment triangle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features of the PAT that are specific for the evaluation of shock include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant changes in appearance (such as poor tone, unfocused gaze, or weak cry) may be indicators of decreased cerebral perfusion. Subtle differences in appearance (such as decreased responsiveness to caretakers or painful procedures) may be indicators of shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child with depressed mental status as the result of shock may not be able to maintain a patent airway. Tachypnea without respiratory distress can develop in response to metabolic acidosis. Children with cardiogenic shock typically have some increased work of breathing in addition to tachypnea.",
"   </p>",
"   <p>",
"    Children with severe respiratory distress and signs of circulatory compromise may have obstructive shock and require life-saving interventions to treat one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tension pneumothorax",
"      </strong>",
"      &ndash; Signs of tension pneumothorax include respiratory distress, decreased breath sounds over the involved hemithorax, subcutaneous air, and distended neck veins. Children with tension pneumothorax frequently have sustained thoracic trauma, although a spontaneous pneumothorax can develop tension. Treatment consists of needle decompression followed by chest tube thoracostomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link&amp;anchor=H7#H7\">",
"       \"Initial evaluation and stabilization of children with thoracic trauma\", section on 'Initial rapid assessment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=see_link&amp;anchor=H5360124#H5360124\">",
"       \"Initial evaluation and stabilization of children with thoracic trauma\", section on 'Chest decompression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiac tamponade",
"      </strong>",
"      &ndash; Features that may be seen with cardiac tamponade include respiratory distress, muffled heart tones, pulsus paradoxus, and distended neck veins. Cardiac tamponade can occur as the result of penetrating thoracic trauma or from the accumulation of fluid as the result of infection, malignancy, or following cardiac surgery (",
"      <a class=\"graphic graphic_movie graphicRef64027 \" href=\"UTD.htm?29/24/30094\">",
"       movie 1",
"      </a>",
"      ). Pericardiocentesis is emergently indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H18957925#H18957925\">",
"       \"Causes of acute respiratory compromise in children\", section on 'Cardiac tamponade'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"       \"Emergency pericardiocentesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Ductal-dependent congenital heart disease",
"      </strong>",
"      &ndash; Infants with ductal-dependent congenital heart disease may have respiratory distress, circulatory collapse, cyanosis not responsive to oxygen administration, cardiomegaly,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a pulse or blood pressure gradient between the upper and lower extremities. Identification and management of infants with congenital heart disease is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link&amp;anchor=H24#H24\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\", section on 'Initial management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Massive pulmonary embolism (PE)",
"      </strong>",
"      &ndash; Findings that suggest PE include cyanosis, respiratory distress, and pleuritic chest pain. PE occurs uncommonly in children. There is typically a predisposing condition (such as a central venous access device or an inherited hypercoagulable state). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\", section on 'Pulmonary embolism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor perfusion can often be identified rapidly, before a blood pressure measurement is taken. Features of circulation that should be quickly evaluated include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Quality of central and peripheral pulses",
"      </strong>",
"      &ndash; Decreased intensity of distal pulses in comparison to central pulses suggests peripheral vasoconstriction and compensated shock. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link&amp;anchor=H7#H7\">",
"       \"Assessment of perfusion in pediatric resuscitation\", section on 'Peripheral versus central pulses'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Bounding pulses may be present in patients with distributive (&ldquo;warm&rdquo;) shock",
"     </li>",
"     <li>",
"      <strong>",
"       Skin temperature",
"      </strong>",
"      &ndash; Skin may be mottled or cool in children with compensated shock, but this finding can also be influenced by environmental temperature.",
"     </li>",
"     <li>",
"      <strong>",
"       Capillary refill",
"      </strong>",
"      &ndash; Capillary refill greater than two seconds suggests shock. The usefulness of capillary refill is limited by interobserver variability and by the effect of environmental temperature. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link&amp;anchor=H4#H4\">",
"       \"Assessment of perfusion in pediatric resuscitation\", section on 'Skin examination and capillary refill'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Flash capillary refill (&lt;1 second) may be present in patients with distributive (&ldquo;warm&rdquo;) shock",
"     </li>",
"     <li>",
"      <strong>",
"       Heart rate",
"      </strong>",
"      &ndash; Tachycardia is frequently present (",
"      <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"       table 3",
"      </a>",
"      ) although a normal heart rate with signs of compensated or decompensated shock can occur with spinal cord injury.",
"      <br/>",
"      <br/>",
"      Hypoxia and some poisonings (eg, beta and calcium channel ingestions) can cause bradycardia (",
"      <a class=\"graphic graphic_table graphicRef51200 \" href=\"UTD.htm?29/8/29838\">",
"       table 4",
"      </a>",
"      ). Bradycardia can also be an agonal event for patients with shock from any cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following historical features may identify the condition causing shock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of fluid loss (due to gastroenteritis, diabetic ketoacidosis, or a gastrointestinal bleed) is consistent with hypovolemic shock. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H5#H5\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\", section on 'History'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children who have been injured may have hypovolemic shock from hemorrhage (eg, solid organ injury from blunt abdominal trauma), obstructive shock (eg, tension pneumothorax or cardiac tamponade),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurogenic shock (eg, spinal cord injury). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H12#H12\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Circulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunocompromise (due to chemotherapy, sickle cell disease, or inherited immunodeficiencies) may indicate septic shock.",
"     </li>",
"     <li>",
"      A history of exposure to an allergen (eg, a bee sting or food) suggests anaphylactic shock.",
"     </li>",
"     <li>",
"      Shock may develop as the result of exposure to toxins (eg, iron, arsenic, beta blockers, calcium channel blockers, or cardiac glycosides).",
"     </li>",
"     <li>",
"      Patients with chronic heart disease (eg, cardiomyopathy or complex congenital heart disease) may have cardiogenic shock.",
"     </li>",
"     <li>",
"      Adrenal crisis must be considered in a patient at risk for adrenal insufficiency (eg, patients receiving chronic steroid therapy, hypopituitarism, neonates with congenital adrenal disease, or sepsis) (",
"      <a class=\"graphic graphic_table graphicRef61357 \" href=\"UTD.htm?22/54/23405\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination, including vital signs with pulse oximetry, should be performed (",
"    <a class=\"graphic graphic_table graphicRef51186 \" href=\"UTD.htm?2/30/2540\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78097 \" href=\"UTD.htm?27/37/28252\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An accurate weight is essential for determining fluid requirements and medication doses. The child's length provides a reasonable estimate of weight when a weight cannot be measured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Estimation of weight'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Capnography may be helpful for identifying hyperventilation in response to metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/6\">",
"     6",
"    </a>",
"    ]. A falsely low EtCO2 can also occur in the setting of poor pulmonary perfusion as a component of the shock state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal vital signs provide essential information regarding the severity, classification, and cause of shock.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Respiratory rate",
"      </strong>",
"      &ndash; Children with shock are usually tachypneic.",
"     </li>",
"     <li>",
"      <strong>",
"       Heart rate",
"      </strong>",
"      &ndash; In children, sinus tachycardia is a consistent sign of shock (except for patients with cardiogenic shock from a bradyarrhythmia or spinal cord injury). For patients with compensated shock, it may be the only abnormal vital sign. Other causes of tachycardia with poor perfusion in children include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Supraventricular tachycardia (SVT)",
"      </strong>",
"      &ndash; With SVT, the heart rate is typically &gt;220 beats per minute for infants, &gt;180 beats per minute for older children and adolescents, and relentlessly regular (",
"      <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"       table 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef70842 \" href=\"UTD.htm?11/63/12272\">",
"       waveform 1",
"      </a>",
"      ). Pediatric treatment is discussed in the algorithm and provided separately (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=see_link\">",
"       \"Management of supraventricular tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Ventricular tachycardia (VT)",
"      </strong>",
"      &ndash; VT is an uncommon rhythm in children that can be identified by electrocardiogram (",
"      <a class=\"graphic graphic_waveform graphicRef76976 \" href=\"UTD.htm?19/49/20249\">",
"       waveform 2",
"      </a>",
"      ). Initial pediatric treatment is provided in the algorithm and discussed separately (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=see_link&amp;anchor=H5#H5\">",
"       \"Management and evaluation of wide QRS complex tachycardia in children\", section on 'Initial evaluation of stable patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Blood pressure",
"      </strong>",
"      &ndash; Children with shock may have normal blood pressures. Hypotension must be rapidly identified, because those with low blood pressures typically deteriorate rapidly to cardiovascular collapse and cardiopulmonary arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/2\">",
"       2",
"      </a>",
"      ]. Measurement with a manual cuff may be more accurate for children with circulatory compromise. Blood pressures determined with automated oscillometric devices can be higher than those using manual devices, particularly for hypotensive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14104/abstract/7\">",
"       7",
"      </a>",
"      ]. For children with normal systolic blood pressures, the classification of shock may be suggested by changes in the pulse pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Narrow pulse pressure (typically &lt;30 mmHg in older children and adults) occurs when diastolic blood pressure is increased as the result of a compensatory increase in systemic vascular resistance (such as with hypovolemic and cardiogenic shock).",
"     </li>",
"     <li>",
"      Widening of pulse pressure (typically &gt;40 mmHg in older children and adults; lower pulse pressures may reflect widening in infants and neonates) can be seen when diastolic blood pressure is decreased as the result of decreased systemic vascular resistance (as can occur with distributive shock).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Temperature",
"      </strong>",
"      &ndash; Fever (or hypothermia in young infants) is often consistent with septic shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional features of the physical examination that suggest the etiology of shock include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stridor, wheezing, or abnormal breath sounds",
"      </strong>",
"      &ndash; Children with stridor or wheezing may have anaphylaxis. Those with crackles may have a pneumonia (septic shock) or heart failure (cardiogenic shock). Those with asymmetric breath sounds may have a tension pneumothorax. Airway obstruction from other causes (such as foreign body aspiration or status asthmaticus) may lead to cardiovascular collapse from hypoxemia.",
"     </li>",
"     <li>",
"      <strong>",
"       Distended neck veins",
"      </strong>",
"      &ndash; Distended neck veins suggest an abnormality of cardiac contractility caused by heart failure, or obstruction to venous return from cardiac tamponade or tension pneumothorax.",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal heart sounds",
"      </strong>",
"      &ndash; Cardiogenic shock is suggested by cardiac murmurs, a gallop rhythm, or muffled heart tones (pericardial fluid)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulse differential",
"      </strong>",
"      &ndash; Decreased pulses",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood pressure in the lower extremities when compared to the upper extremities suggests coarctation of the aorta or other structural heart disease.",
"     </li>",
"     <li>",
"      <strong>",
"       Hepatomegaly",
"      </strong>",
"      &ndash; Hepatic congestion and resulting hepatomegaly can be seen with heart failure",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal abdominal findings",
"      </strong>",
"      &ndash; Abdominal distention, masses, or tenderness is consistent with an abdominal catastrophe such as bowel obstruction, perforation, or peritonitis. Inflicted injury should be considered in the absence of a plausible history of trauma.",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal skin findings",
"      </strong>",
"      &ndash; Urticaria or facial edema suggests anaphylaxis but is",
"      <strong>",
"       not",
"      </strong>",
"      a consistent finding in severe reactions. Purpura can be seen with septic shock. Bruises",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abrasions may be noted with trauma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected ancillary studies may be useful for successfully treating shock, identifying the etiology, and monitoring response to treatment. Treatment should be initiated and ancillary studies based upon the most likely etiology for shock should be obtained simultaneously.",
"   </p>",
"   <p>",
"    Patients with suspected hypovolemic shock warrant the following laboratory and diagnostic studies (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H7#H7\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Ancillary data'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid blood glucose",
"     </li>",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      Hematocrit",
"     </li>",
"     <li>",
"      Arterial or venous blood gas measurements",
"     </li>",
"     <li>",
"      Type and cross match (patients with trauma and hemorrhagic shock)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A chest radiograph in children with suspected hypovolemic shock who do not rapidly improve after up to 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic fluid administration is also suggested. If the heart size is small, then additional bolus fluid administration is indicated. In contrast, if the heart is big, then fluid therapy should be moderated and additional types of shock (eg, septic or cardiogenic shock) may be present and warrant specific therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial management of shock in children\", section on 'Specific management decisions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with traumatic hemorrhagic shock, a chest radiograph may also identify intrathoracic bleeding (ie, hemothorax) or other causes for shock, such as tension pneumothorax or pericardial effusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H23#H23\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Screening radiographs'",
"    </a>",
"    .) Bedside focused assessment with sonography for trauma (FAST) can rapidly identify pericardial effusion and serious intraabdominal hemorrhage. Additional imaging is typically warranted for these patients. The approach to imaging in the pediatric trauma patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H21#H21\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Adjuncts to the primary survey'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H37#H37\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Adjuncts to the secondary survey'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with abdominal findings, plain radiography of the abdomen may identify signs of bowel obstruction or perforation. Additional imaging is usually warranted to establish a definitive diagnosis (eg, ultrasound for intussusception, upper gastrointestinal series for malrotation, or computed tomography for intraabdominal abscess). See related topics.",
"   </p>",
"   <p>",
"    Children with abnormal cardiac examinations or who are not improving with initial treatment should receive electrocardiograms to evaluate for arrhythmias or signs of ischemia. Depending upon specific findings, consultation with a pediatric cardiologist and echocardiography may be warranted.",
"   </p>",
"   <p>",
"    Suggested laboratory studies and imaging for children in with suspected septic shock are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H14817539#H14817539\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Laboratory studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H14817575#H14817575\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL CLASSIFICATION OF SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the initial evaluation is completed, a constellation of clinical characteristics suggest a specific type of shock (",
"    <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"     algorithm 1",
"    </a>",
"    ). A patient may have more than one type of shock (such as an infant with cardiogenic shock from supraventricular tachycardia who is also hypovolemic because he has been unable to drink, or a child with underlying cardiomyopathy who is septic).",
"   </p>",
"   <p>",
"    Patterns that may be helpful include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypovolemic shock",
"      </strong>",
"      &ndash; History of volume loss (including hemorrhage associated with trauma), narrow pulse pressure, signs of poor peripheral perfusion (decreased distal pulses, cool extremities, prolonged capillary refill), small heart on chest radiograph (if one is obtained) (",
"      <a class=\"graphic graphic_table graphicRef76198 \" href=\"UTD.htm?13/5/13404\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H4#H4\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Septic shock",
"      </strong>",
"      &ndash; History of fever or immunocompromise, wide pulse pressure, variable peripheral perfusion (vasodilation with warm shock, vasoconstriction with cold shock), purpuric rash, abnormal white blood cell count, disseminated intravascular coagulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link&amp;anchor=H1374240#H1374240\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anaphylactic shock",
"      </strong>",
"      &ndash; History of exposure to an allergen (such as a bee sting or food), stridor, wheezing, wide pulse pressure, vasodilation, urticaria, facial edema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H2#H2\">",
"       \"Anaphylaxis: Rapid recognition and treatment\", section on 'Definition and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Neurogenic shock",
"      </strong>",
"      &ndash; History of trauma, hypotension with wide pulse pressure, normal heart rate or bradycardia.",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiogenic shock",
"      </strong>",
"      &ndash; History of heart disease, central cyanosis, signs of heart failure (rales, hepatomegaly, gallop rhythm, distended jugular veins), heart murmur, decreased pulses",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood pressure in the lower extremities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12201101\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive management of shock depends upon correct classification of the type of shock present and definitive treatment of the underlying etiology. The initial management of undifferentiated shock is provided in the algorithm and discussed in detail separately (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial management of hypovolemic and septic shock are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450185#H19450185\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shock develops as the result of conditions that cause decreased intravascular volume (hypovolemic shock), abnormal distribution of intravascular volume (distributive shock), or impaired cardiovascular function (cardiogenic shock) (",
"      <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of the evaluation of shock are to identify life threatening conditions and to rapidly recognize children with circulatory compromise so that treatment can be initiated before hypotension develops. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid assessment of appearance, breathing, and circulation should identify children with life-threatening conditions, including hypotension, and many of those with compensated shock. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Rapid assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features often suggest the cause of shock and can be used to guide management decisions (",
"      <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clinical classification of shock'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial management of shock in children\", section on 'Specific management decisions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Definitive management of pediatric shock depends upon correct classification of the type of shock based upon clinical findings and definitive treatment of the underlying etiology. The initial management of undifferentiated shock is provided in the algorithm and discussed in detail separately (",
"      <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=see_link\">",
"       \"Initial management of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14104/abstract/1\">",
"      Schwaitzberg SD, Bergman KS, Harris BH. A pediatric trauma model of continuous hemorrhage. J Pediatr Surg 1988; 23:605.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual. Hazinski MF, Samson RA, Schexnayder SM (Eds). American Heart Association, Dallas, 2012.",
"    </li>",
"    <li>",
"     World health statistics 2012. World Health Organization, WHO press, Geneva, Switzerland, 2012. file://www.who.int/gho/publications/world_health_statistics/2012/en/index.html (Accessed on November 13, 2012).",
"    </li>",
"    <li>",
"     National Center for Injury Preventions and Control www.cdc.gov/ncipc/wisqars/ (Accessed on June 01, 2007).",
"    </li>",
"    <li>",
"     Bell LM. Shock. In: Textbook of Pediatric Emergency Medicine, 6th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.46.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14104/abstract/6\">",
"      Jin X, Weil MH, Tang W, et al. End-tidal carbon dioxide as a noninvasive indicator of cardiac index during circulatory shock. Crit Care Med 2000; 28:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14104/abstract/7\">",
"      Davis JW, Davis IC, Bennink LD, et al. Are automated blood pressure measurements accurate in trauma patients? J Trauma 2003; 55:860.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6396 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14104=[""].join("\n");
var outline_f13_49_14104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rapid assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL CLASSIFICATION OF SHOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12201101\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6396|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/61/2000\" title=\"algorithm 1\">",
"      Undifferentiated pediatric shock algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/12/42178\" title=\"algorithm 2\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 3\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6396|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/24/30094\" title=\"movie 1\">",
"      Pericardial effusion with tamponade subcostal view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6396|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/34/17963\" title=\"table 1\">",
"      Types of shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/34/38445\" title=\"table 2\">",
"      Causes of cardiogenic shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/37/28252\" title=\"table 3\">",
"      Normal respiratory rate and heart rate in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/8/29838\" title=\"table 4\">",
"      Drug and toxin related pulse changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/54/23405\" title=\"table 5\">",
"      Rapid overview adrenal crisis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/30/2540\" title=\"table 6\">",
"      Blood pressure children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/42/22189\" title=\"table 7\">",
"      Pediatric supraventricular tachycardia rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13404\" title=\"table 8\">",
"      Pediatric signs of dehydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6396|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/63/12272\" title=\"waveform 1\">",
"      Conversion of supraventricular tachycardia with adenosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?19/49/20249\" title=\"waveform 2\">",
"      12 lead ECG CPVT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=related_link\">",
"      Causes of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=related_link\">",
"      Diagnosis and initial management of cyanotic heart disease in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=related_link\">",
"      Physiology and classification of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_49_14105="Evaluation of severe asthma in adolescents and adults";
var content_f13_49_14105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of severe asthma in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14105/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14105/contributors\">",
"     Sally Wenzel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14105/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14105/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/49/14105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe asthma afflicts 5 to 10 percent of the asthma population, but drives the majority of the morbidity and costs of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinician must first determine that a patient with severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent respiratory symptoms suggestive of severe asthma has been given the correct diagnosis. Alternative possibilities include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asthma that is exacerbated by uncontrolled triggers",
"     </li>",
"     <li>",
"      Asthma that is poorly controlled because of nonadherence",
"     </li>",
"     <li>",
"      An alternative",
"      <span class=\"nowrap\">",
"       disorder/disease",
"      </span>",
"      that mimics asthma",
"     </li>",
"     <li>",
"      Asthma that is exacerbated by a comorbid condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will address the approach to a patient with symptoms suggestive of severe asthma. The general approach to asthma diagnosis and treatment and a discussion of asthma phenotypes and their influence on treatment are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36278?source=see_link\">",
"     \"Severe asthma: Evidence for heterogeneity of the disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link\">",
"     \"Treatment of severe asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We reserve the classification of \"severe asthma\" for patients who require high dose inhaled or near continuous oral glucocorticoid treatment to maintain asthma control. This is delineated in the working definition of severe asthma proposed by the American Thoracic Society that requires the presence of one or both major criteria and at least two minor criteria (",
"    <a class=\"graphic graphic_table graphicRef68983 \" href=\"UTD.htm?12/20/12620\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/2\">",
"     2",
"    </a>",
"    ]. Other conditions must have been evaluated and excluded; potential exacerbating factors remediated; and lack of adherence determined not to be a significant contributor to poor asthma control.",
"   </p>",
"   <p>",
"    The 2007 NAEPP guidelines include a category of \"severe asthma\" among patients who are not initially on controller medication (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/3\">",
"     3",
"    </a>",
"    ]. Some patients who are in this category before therapy are able to achieve asthma control with moderate doses of inhaled glucocorticoids and thus do not meet criteria for severe persistent asthma. In patients with severe persistent asthma, attempts at lowering the glucocorticoid dose lead to deterioration in asthma control (",
"    <a class=\"graphic graphic_table graphicRef65972 \" href=\"UTD.htm?15/31/15869\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating a patient with symptoms suggestive of severe asthma, the key factors to identify are those that differentiate asthma from its mimics and those that increase the risk of exacerbations. As with less severe asthma, information about uncontrolled triggers, barriers to adherence, and contributing comorbidities should be sought [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important elements of the history in patients with severe asthma are reviewed here. The history and physical examination findings that are typical of asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Characterize the specific symptoms (eg, dyspnea, cough, wheeze, chest tightness, sputum), their frequency and severity. Symptoms that may suggest a nonasthma diagnosis include hoarseness, prominent sputum production, constitutional symptoms, and lack of improvement with appropriate asthma medication.",
"     </li>",
"     <li>",
"      Clarify when symptoms began: childhood onset of symptoms favors a diagnosis of atopic asthma. Asthma is diagnosed in childhood in approximately 75 percent of all asthma patients; however adult onset asthma tends to be more severe and less likely allergic [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Identify temporal patterns of symptoms: nocturnal symptoms suggest greater asthma severity, although gastroesophageal reflux disease (GERD) and obstructive sleep apnea may also cause nocturnal choking and dyspnea.",
"     </li>",
"     <li>",
"      Determine the severity of exacerbations: previous emergency department visits, hospitalizations,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      invasive mechanical ventilation imply a greater risk of future severe asthma exacerbations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional helpful questions include whether asthma symptoms vary with the menstrual cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/6\">",
"     6",
"    </a>",
"    ]; whether symptoms began after an upper respiratory infection (may suggest bronchiolitis); and if the patient has had pneumonia or recurrent bronchitis (may suggest bronchiectasis).",
"   </p>",
"   <p>",
"    The physical examination should include a thorough",
"    <span class=\"nowrap\">",
"     nasal/sinus",
"    </span>",
"    evaluation, looking for stigmata of nasal obstruction, nasal polyposis, sinusitis, and allergic rhinitis; examination of the neck for masses and tracheal deviation; a complete cardiopulmonary exam, looking for focal versus diffuse wheeze, stridor, situs inversus and evidence of alternative diagnoses (eg, crackles suggestive of hypersensitivity pneumonitis, cryptogenic organizing pneumonitis, interstitial lung disease, or heart failure); and skin examination looking for stigmata of atopic dermatitis, sarcoidosis, and vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Trigger identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing exposures to triggers in any setting may contribute to poor asthma control, so the patient's home, school, and work environments should be carefully reviewed. Triggers may be inhaled (eg, allergens, irritants) or ingested (eg, NSAID and beta blocker medications). A series of potential questions is given in the table (",
"    <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occupational allergic asthma may not be immediately apparent; patients should be asked about workplace exposures to inhaled allergens, such as laboratory animals, latex, glutaraldehyde, toluene diisocyanate, and flour. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    .) Some of the antigens may cause both asthma and hypersensitivity pneumonitis. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Conditions that mimic asthma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with severe asthma, additional pulmonary function testing beyond spirometry is warranted. The most helpful testing includes pre- and post-bronchodilator spirometry with inspiratory and expiratory flow loops, lung volumes, and diffusing capacity. Confirmation of the asthma diagnosis requires evidence of expiratory airflow limitation with a bronchodilator response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent airflow limitation is seen in about 50 percent of patients with severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, air trapping, as manifest by a reduced FVC and increased residual volume and total lung capacity (on plethysmographic pulmonary function testing), is characteristic of severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/8\">",
"     8",
"    </a>",
"    ]. In cases where there is a minimal expiratory airflow limitation, often in the face of a high degree of symptoms, a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge can determine the presence of hyperreactive airways or, in conjunction with laryngoscopy, confirm vocal cord dysfunction. The diffusing capacity is typically normal or increased in asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link\">",
"     \"Bronchoprovocation testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=see_link\">",
"     \"Diffusing capacity for carbon monoxide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lab/immunologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no laboratory tests that confirm or exclude asthma, but testing can help to evaluate associated conditions and asthma triggers. For patients with severe persistent asthma, a CBC and differential (primarily to evaluate the",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of eosinophils and exclude anemia as a cause of dyspnea), IgE level (eg, for allergic bronchopulmonary aspergillosis or for identification of patients in whom anti-IgE therapy might be considered), and an antineutrophil cytoplasmic antibody (ANCA) for Churg-Strauss can be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the lifelong non-smoker with persistent and irreversible airflow obstruction, a one-time measurement of the serum alpha-1 antitrypsin level is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient has not had specific allergy testing, either allergy skin tests or specific RAST should be done, particularly if environmental factors are suspected triggers (eg, a cat or dog in the household). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis of asthma in adolescents and adults\", section on 'Tests for allergy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients from endemic areas, eosinophilia may be a manifestation of Strongyloides or filarial infection and can be further evaluated with specific antibody testing. In patients born in developed countries, eosinophilia is more likely to be due to adult onset (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -sensitive) asthma, allergic bronchopulmonary aspergillosis, or rarely, Churg Strauss syndrome. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Conditions that mimic asthma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with persistent dyspnea that is not well-explained by the degree of airflow limitation noted on pulmonary function tests, measurement of B-type natriuretic peptide (BNP) may help to exclude cardiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Airway inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated eosinophilia in induced sputum and on endobronchial biopsy to determine whether persistent inflammation might be contributing to poor asthma control [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/5,7,9,10\">",
"     5,7,9,10",
"    </a>",
"    ]. The presence of sputum eosinophils despite high dose inhaled or oral glucocorticoids has been associated with more symptomatic disease and worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/11\">",
"     11",
"    </a>",
"    ]. Furthermore, in two studies of moderate to severe asthma, evaluation and treatment of the level of eosinophilic inflammation present in sputum samples lead to better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Some patients with severe asthma have elevated sputum neutrophil counts, raising the possibility that they have an alternate asthma pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/5,9,12-15\">",
"     5,9,12-15",
"    </a>",
"    ]. However, sputum analyses must be done by a trained technician to standardize both collection and cell counting and the significance of these findings is still under investigation.",
"   </p>",
"   <p>",
"    Obtaining endobronchial biopsies to assess eosinophilic inflammation carries greater risk than induced sputum and should only be performed at institutions where quantitative measurements are commonly obtained. Bronchoscopy can also be helpful to evaluate interstitial findings on CT scanning, for example when chronic eosinophilic pneumonia or hypersensitivity pneumonitis are suspected.",
"   </p>",
"   <p>",
"    Exhaled nitric oxide has also been used to assess ongoing airway inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Management of patients by monitoring and treatment of exhaled nitric oxide, though much easier to collect than sputum, has not been shown to be of clear clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=see_link\">",
"     \"Exhaled nitric oxide analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest x-ray should be performed in patients with symptoms suggestive of severe asthma, even though this would not be indicated in the routine evaluation of asthma. If interstitial opacities are noted on the chest x-ray or if the diffusing capacity (DLCO) is reduced, a high resolution CT (HRCT) scan of the thorax should be performed to assess for interstitial lung disease and bronchiolitis. When trying to discriminate between severe asthma and bronchiolitis, the presence of a mosaic attenuation pattern makes bronchiolitis more likely [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HRCT can also be helpful in identifying bronchiectasis, tracheal strictures and masses, and vascular anomalies that mimic asthma (eg, right sided aortic arch and aberrant left subclavian) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"     \"Vascular rings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gender differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe asthma is likely to be more common in women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/12\">",
"     12",
"    </a>",
"    ]. However, women with severe asthma generally have more favorable objective findings than men, such as a better FEV1 and",
"    <span class=\"nowrap\">",
"     FEV1/FVC,",
"    </span>",
"    and lower total and specific IgE and FeNO.",
"   </p>",
"   <p>",
"    Women frequently describe greater allergic (and general) symptoms, have lower asthma specific quality of life, are more likely to be obese, and have more frequent and severe exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/12\">",
"     12",
"    </a>",
"    ]. Women with premenstrual asthma appear to be at a particularly high risk of severe asthma exacerbations. While the reasons for this more symptomatic disease in women as compared to men remain unknown, it is important to consider severe asthma in women despite lesser (but not absent) objective findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MEDICATION ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incomplete",
"    <span class=\"nowrap\">",
"     compliance/adherence",
"    </span>",
"    to medication is present in many, if not all, chronic diseases and generally to the same degree (approximately 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/22\">",
"     22",
"    </a>",
"    ]. Asthma is no exception, so",
"    <span class=\"nowrap\">",
"     compliance/adherence",
"    </span>",
"    to medications must always be addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Compliance/adherence",
"    </span>",
"    should be encouraged in a non-judgmental manner (especially if a medication is known to be helpful to that patient), and reasons behind non-adherence explored (eg, fear of side effects or dependence, forgetfulness, cost of medication). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12789?source=see_link\">",
"     \"Enhancing patient adherence to asthma therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overall understanding of the patient's social situation regarding access to medical care, medications and their costs is also important.",
"   </p>",
"   <p>",
"    If available, pharmacy records can supplement patient report of adherence. Additionally, in patients on oral glucocorticoids, a fasting morning cortisol of &lt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    is helpful to measure compliance, as is the presence of steroid side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CONDITIONS THAT MIMIC ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions share a symptom complex and can be confused with severe asthma; the most common ones presenting to an asthma specialty clinic are reviewed here (",
"    <a class=\"graphic graphic_table graphicRef52599 \" href=\"UTD.htm?24/20/24909\">",
"     table 5",
"    </a>",
"    ). In addition, some of the conditions that mimic asthma may also accompany asthma including: vocal cord dysfunction, allergic bronchopulmonary aspergillosis, COPD, chronic eosinophilic pneumonia, and Churg-Strauss syndrome. These conditions cause the asthma to appear more severe, and require specific treatment separate from asthma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vocal cord dysfunction &ndash; The most common masquerader of severe asthma is vocal cord dysfunction (VCD), also known as paradoxical vocal cord motion (PVCM) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. This syndrome involves involuntary closure of the vocal cords, commonly during inspiration, and can be seen in both men and women. Symptoms include episodic and severe shortness of breath, wheezing, and intractable cough, often in response to irritant exposures (perfumes) or exercise. Patients may have concomitant dysphonia and frequently report an \"inability to get enough air (in)\". This diagnosis can be made using a combination of inspiratory flow volume loops and laryngoscopy during symptoms, possibly performed at the time of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      or exercise challenge (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulmonary function tests'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      It is important to note that VCD can also occur in the presence of severe asthma. It is often worsened by factors that also worsen asthma, including post nasal drip, GERD and anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=see_link\">",
"       \"Paradoxical vocal cord motion\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Vocal cord paralysis and vocal cord lesions are associated with exertional dyspnea and, frequently, dysphonia. A history of intubation, trauma, or surgery with potential injury to the laryngeal nerve would be a clue to evaluate these diagnoses further. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=see_link\">",
"       \"Hoarseness in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central airway obstruction &ndash; Central airway obstruction includes tracheal strictures (eg, from prior intubation), tracheal compression by goiter, tracheal and proximal bronchial tumors, and vascular rings [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/19\">",
"       19",
"      </a>",
"      ]. Patients may present with exertional dyspnea and, sometimes, monophonic wheeze or stridor.",
"      <br/>",
"      <br/>",
"      A flow volume loop including the inspiratory phase is the first step in evaluation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulmonary function tests'",
"      </a>",
"      above.) Chest computed tomography (CT) may detect airway compromise, but the test as routinely performed is not sensitive. If an airway lesion is suspected, a high resolution CT (HRCT) with three-dimensional airway reconstruction can prove helpful, but direct visualization is usually needed for definitive diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"       \"Diagnosis and management of central airway obstruction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic obstructive pulmonary disease &ndash; COPD should be considered in patients with greater than a 20 pack year smoking history or a family history of emphysema or alpha-1 antitrypsin deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to the history of smoking, clues to the presence of COPD include irreversible airflow obstruction and the combination of airflow obstruction and a low diffusing capacity (DLCO). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"       \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchiectasis &ndash; Patients with bronchiectasis typically have a chief complaint of productive cough, and the amount of sputum production is usually more than what would be expected in pure asthma. An end-inspiratory squeak may be heard on physical exam that can mimic a wheeze. The cough is typically refractory to bronchodilator therapy. HRCT of the thorax will help determine whether bronchiectasis is present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Allergic bronchopulmonary aspergillosis (ABPA) may develop in patients with asthma due to colonization of the airways with aspergillus and typically presents with recurrent mucoid impaction and atelectasis. The resulting immunologic reaction leads to proximal bronchiectasis. ABPA should be suspected in patients who have skin test positivity to aspergillus and elevated IgE levels (&gt;1000",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link\">",
"       \"Allergic bronchopulmonary aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bronchiolitis &ndash; Several bronchiolar diseases share features of asthma, such as cough and dyspnea that worsens with exertion. Bronchiolitis is typically a consequence of a respiratory infection, inhalational injury, organ transplantation, or connective tissue disease. Physical exam may reveal crackles and inspiratory squeaks; pulmonary function tests show progressive airflow obstruction not responsive to bronchodilator; DLCO and oxygen saturation are reduced; and chest CT scan will show interstitial opacities in a mosaic pattern [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/18\">",
"       18",
"      </a>",
"      ]. Inspiratory and expiratory views on HRCT may reveal patchy areas of air trapping. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"       \"Bronchiolitis in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Cryptogenic organizing pneumonia (also known as bronchiolitis obliterans organizing pneumonia or BOOP) is usually manifest by a nonproductive cough, sometimes dyspnea, systemic symptoms of malaise, and sometimes fever. Crackles are usually noted on chest exam and an HRCT reveals interstitial opacities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      patchy areas of consolidation. Pulmonary function tests typically show a restrictive pattern; airflow limitation is seen uncommonly and generally only in cigarette smokers. Usually, a lung biopsy is required for diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"       \"Cryptogenic organizing pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypersensitivity pneumonitis &ndash; Patients with hypersensitivity pneumonitis (HP) may report intermittent dyspnea than can be confused with asthma. Exposure to allergens that typically cause HP (eg, birds, barns, humidifiers) should alert the clinician to this possibility. Pulmonary function tests may show a mixed obstructive and restrictive pattern and a reduced DLCO. Fleeting infiltrates are another clue. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=see_link\">",
"       \"Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophilia and respiratory symptoms &ndash; Filarial and strongyloides infections and Churg-Strauss syndrome may present with asthma that cannot be controlled until the underlying disease is treated. Filarial and strongyloides infection should be suspected in patients from an endemic area, who have blood eosinophilia and an elevated IgE level. Specific IgG antibodies to filarial and strongyloides antigens will be positive. Improvement with specific treatment confirms the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=see_link\">",
"       \"Tropical filarial pulmonary eosinophilia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link\">",
"       \"Strongyloidiasis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with Churg-Strauss syndrome and chronic eosinophilic pneumonia (CEP) may have asthma, but also have other findings (eg, blood eosinophilia, pulmonary infiltrates). Paranasal sinus disease, skin lesions, a peripheral neuropathy, and eosinophilia &gt;10 percent are common in Churg-Strauss, although blood eosinophilia may be masked by systemic glucocorticoids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"       \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=see_link\">",
"       \"Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Concomitant fever, weight loss, and night sweats are often seen in CEP; blood eosinophilia may be absent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link&amp;anchor=H10#H10\">",
"       \"Causes of pulmonary eosinophilia\", section on 'Chronic eosinophilic pneumonia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sarcoidosis &ndash; Endobronchial sarcoidosis may present with a refractory cough and dyspnea. Chest x-ray and CT will likely show typical findings of hilar adenopathy and interstitial opacities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac disease &ndash; Heart failure may mimic asthma in older adults and can be evaluated with B-type natriuretic peptide (BNP), chest x-ray, and echocardiogram. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=see_link&amp;anchor=H19#H19\">",
"       \"Diagnosis and management of asthma in older adults\", section on 'Heart failure versus asthma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMORBIDITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once alternative diagnoses have been excluded and the diagnosis of asthma confirmed, the contribution of comorbid conditions to disease severity should be evaluated (",
"    <a class=\"graphic graphic_table graphicRef61331 \" href=\"UTD.htm?4/59/5053\">",
"     table 6",
"    </a>",
"    ). Addressing these issues may reduce asthma symptoms in some patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic rhinosinusitis &ndash; Chronic rhinosinusitis is a frequent comorbid condition and is an independent risk factor for exacerbations of asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/30\">",
"       30",
"      </a>",
"      ]. At least some studies in milder asthma suggest that improved upper airway therapy leads to better asthma outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Allergic rhinitis symptoms and signs should be evaluated and the nose examined for nasal polyps. Patients with nasal polyposis and asthma are likely to have",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exacerbated respiratory disease (AERD) and to have sudden and life threatening flares of asthma after ingestion of aspirin or NSAIDs. Even in the absence of aspirin or NSAID ingestion, they are likely to have severe asthma symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=see_link\">",
"       \"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients with severe asthma, at least one sinus computed tomography (CT) scan looking for chronic rhinosinusitis is probably appropriate, although studies to demonstrate the cost efficacy of this test are not available. Multiplanar sinus CT scan is the preferred imaging modality when evaluating for comorbid chronic rhinosinusitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H32#H32\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Sinus CT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastroesophageal reflux &ndash; Gastroesophageal reflux disease (GERD) is commonly seen in association with severe asthma, but whether treatment improves asthma remains controversial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=see_link\">",
"       \"Gastroesophageal reflux and asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking &ndash; Several studies report that asthmatics who smoke are at increased risk for exacerbations, have impaired lung function, and respond poorly to inhaled glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Every effort should be made for the patient to quit; patients should also understand that ongoing smoking is a risk factor for fatal asthma. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=see_link\">",
"       \"Identifying patients at risk for fatal asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obesity &ndash; Obesity (body mass index &ge;30",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      is common in patients with severe asthma. Obesity has been associated with increased incident asthma in women and with worsened asthma severity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. Unfortunately, weight loss is difficult for patients with severe asthma, particularly when they require systemic glucocorticoids; in addition to the effects of glucocorticoids, activity is often limited by dyspnea.",
"     </li>",
"     <li>",
"      Obstructive sleep apnea &ndash; Obstructive sleep apnea (OSA) is a common disorder that may occur together with asthma and share certain predisposing factors [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. Both obesity and nasal congestion (eg, from allergic rhinitis or nasal polyposis) may further contribute to the development of OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/30,41,42\">",
"       30,41,42",
"      </a>",
"      ]. Daytime sleepiness in patients with asthma is more likely related to OSA than asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/41\">",
"       41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Polysomnography is suggested in patients with symptoms and clinical features suggestive of OSA, particularly when nocturnal symptoms are persistent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychiatric disorders &ndash; Psychiatric disorders have long been associated with severe asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/43-47\">",
"       43-47",
"      </a>",
"      ]. In one study, anxiety and depression were present to a much greater degree in patients with severe asthma than the normal population and were a risk factor for more severe asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/44\">",
"       44",
"      </a>",
"      ]. However, it is not clear whether the anxiety and depression are truly risk factors for severe asthma or the result of severe asthma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHENOTYPING ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;If, after a thorough evaluation and treatment of confounders, the patient still remains symptomatic and poorly controlled, the patient likely has severe asthma (",
"    <a class=\"graphic graphic_table graphicRef68983 \" href=\"UTD.htm?12/20/12620\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/2\">",
"     2",
"    </a>",
"    ]. Some experts have suggested that patients with severe asthma can be further characterized into phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14105/abstract/5,9,12,13\">",
"     5,9,12,13",
"    </a>",
"    ]. Briefly, emerging evidence suggests that among patients with severe asthma some are atopic and \"early onset\", some have a course characterized by frequent and often severe exacerbations, and others have chronic, sometimes severe, airflow limitation that is only partially reversible. Identification of an eosinophilic inflammatory phenotype may identify severe asthma patients who respond better to increasing glucocorticoid therapy, and eventually to eosinophil specific targeted therapy. These are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36278?source=see_link\">",
"     \"Severe asthma: Evidence for heterogeneity of the disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe asthma are typically in the \"severe persistent asthma\" and \"very poorly controlled\" categories of the NHLBI guidelines. A consensus definition of severe asthma requires at least one major criterion and two minor criteria; other conditions must have been excluded, and exacerbating factors treated (",
"      <a class=\"graphic graphic_table graphicRef68983 \" href=\"UTD.htm?12/20/12620\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important elements in the history include: age of onset of symptoms, exact description of symptoms, temporal pattern of symptoms, exacerbating factors (",
"      <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"       table 4",
"      </a>",
"      ), and family history of atopic disease. Assessment of the frequency and severity of asthma exacerbations helps to predict the risk of future exacerbations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'History and physical'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical masqueraders of severe asthma include (in general order of likelihood): vocal cord dysfunction, chronic obstructive pulmonary disease (COPD), bronchiectasis, hypersensitivity pneumonitis (HP), hypereosinophilic syndromes (including Churg-Strauss syndrome), constrictive bronchiolitis, and endobronchial sarcoidosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Conditions that mimic asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suggested pulmonary function tests include spirometry pre- and post-bronchodilator with inspiratory and expiratory flow loops, lung volumes, and diffusing capacity. Confirmation of the asthma diagnosis requires expiratory airflow limitation with a bronchodilator response or a positive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      challenge. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulmonary function tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing in asthma is rarely diagnostic, but certain tests may be helpful, including CBC and differential, total IgE level, alpha-1 antitrypsin, and ANCA. Specific allergen skin testing or RAST may help identify triggers like dust mites and animal dander. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lab/immunologic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest x-ray and CT scans may help identify diseases that mimic asthma like central airway obstruction, bronchiectasis, bronchiolitis and vascular rings. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chest radiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medication adherence is an important cause of poorly controlled asthma, especially when more complicated treatment regimens become necessary. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Medication adherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comorbid conditions like rhinosinusitis and obesity appear to exacerbate asthma. It is controversial whether GERD exacerbates asthma, but is common among patients with asthma. Obstructive sleep apnea may contribute to nocturnal respiratory symptoms. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Comorbidities'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of severe asthma in adolescents and adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link\">",
"     \"Treatment of severe asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/1\">",
"      Antonicelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilisation. Eur Respir J 2004; 23:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/2\">",
"      Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162:2341.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text available online: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed February 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/4\">",
"      Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/5\">",
"      Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/6\">",
"      Martinez-Morag&oacute;n E, Plaza V, Serrano J, et al. Near-fatal asthma related to menstruation. J Allergy Clin Immunol 2004; 113:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/7\">",
"      ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/8\">",
"      Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008; 104:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/9\">",
"      Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/10\">",
"      Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/11\">",
"      Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/12\">",
"      The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/13\">",
"      Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol 2007; 7:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/14\">",
"      Lee JH, Haselkorn T, Borish L, et al. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007; 132:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/15\">",
"      Shannon J, Ernst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/16\">",
"      Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/17\">",
"      Tseliou E, Bessa V, Hillas G, et al. Exhaled nitric oxide and exhaled breath condensate pH in severe refractory asthma. Chest 2010; 138:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/18\">",
"      Jensen SP, Lynch DA, Brown KK, et al. High-resolution CT features of severe asthma and bronchiolitis obliterans. Clin Radiol 2002; 57:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/19\">",
"      Morel V, Corbineau H, Lecoz A, et al. Two cases of 'asthma' revealing a diverticulum of Kommerell. Respiration 2002; 69:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/20\">",
"      Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/21\">",
"      Fritscher LG, Marras TK, Bradi AC, et al. Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study. Chest 2011; 139:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/22\">",
"      Fallowfield L, Atkins L, Catt S, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/23\">",
"      Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol 2002; 109:S554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/24\">",
"      Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/25\">",
"      Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011; 128:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/26\">",
"      Thomas PS, Geddes DM, Barnes PJ. Pseudo-steroid resistant asthma. Thorax 1999; 54:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/27\">",
"      Low K, Lau KK, Holmes P, et al. Abnormal vocal cord function in difficult-to-treat asthma. Am J Respir Crit Care Med 2011; 184:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/28\">",
"      Balkissoon R. Vocal cord dysfunction, gastroesophageal reflux disease, and nonallergic rhinitis. Clin Allergy Immunol 2007; 19:411.",
"     </a>",
"    </li>",
"    <li>",
"     Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Executive summary 2006. Global Initiative for Chronic Obstructive Lung Disease (GOLD). file://www.goldcopd.org (Accessed on February 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/30\">",
"      ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/31\">",
"      Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/32\">",
"      Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/33\">",
"      Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/34\">",
"      Pedersen SE, Bateman ED, Bousquet J, et al. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study. J Allergy Clin Immunol 2007; 120:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/35\">",
"      Camargo CA Jr, Weiss ST, Zhang S, et al. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/36\">",
"      Rodrigo GJ, Plaza V. Body mass index and response to emergency department treatment in adults with severe asthma exacerbations: a prospective cohort study. Chest 2007; 132:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/37\">",
"      Mosen DM, Schatz M, Magid DJ, Camargo CA Jr. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol 2008; 122:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/38\">",
"      Devouassoux G, L&eacute;vy P, Rossini E, et al. Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness. J Allergy Clin Immunol 2007; 119:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/39\">",
"      Bonekat HW, Hardin KA. Severe upper airway obstruction during sleep. Clin Rev Allergy Immunol 2003; 25:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/40\">",
"      Teodorescu M, Polomis DA, Hall SV, et al. Association of obstructive sleep apnea risk with asthma control in adults. Chest 2010; 138:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/41\">",
"      Teodorescu M, Consens FB, Bria WF, et al. Correlates of daytime sleepiness in patients with asthma. Sleep Med 2006; 7:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/42\">",
"      Yigla M, Tov N, Solomonov A, et al. Difficult-to-control asthma and obstructive sleep apnea. J Asthma 2003; 40:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/43\">",
"      ten Brinke A, Ouwerkerk ME, Bel EH, Spinhoven P. Similar psychological characteristics in mild and severe asthma. J Psychosom Res 2001; 50:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/44\">",
"      Brown ES, Khan DA, Mahadi S. Psychiatric diagnoses in inner city outpatients with moderate to severe asthma. Int J Psychiatry Med 2000; 30:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/45\">",
"      Mancuso CA, Wenderoth S, Westermann H, et al. Patient-reported and physician-reported depressive conditions in relation to asthma severity and control. Chest 2008; 133:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/46\">",
"      Goldney RD, Ruffin R, Fisher LJ, Wilson DH. Asthma symptoms associated with depression and lower quality of life: a population survey. Med J Aust 2003; 178:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14105/abstract/47\">",
"      Lavoie KL, Bouthillier D, Bacon SL, et al. Psychologic distress and maladaptive coping styles in patients with severe vs moderate asthma. Chest 2010; 137:1324.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 564 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14105=[""].join("\n");
var outline_f13_49_14105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Trigger identification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lab/immunologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Airway inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gender differences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MEDICATION ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CONDITIONS THAT MIMIC ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHENOTYPING ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/564|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/20/12620\" title=\"table 1\">",
"      ATS severe asthma criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 2\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/31/15869\" title=\"table 3\">",
"      Asthma control 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/33/35357\" title=\"table 4\">",
"      Asthma trigger questions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/20/24909\" title=\"table 5\">",
"      Evaluation of asthma mimics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/59/5053\" title=\"table 6\">",
"      Evaluation of comorbidities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22362?source=related_link\">",
"      Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5818?source=related_link\">",
"      Diagnosis and management of asthma in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1225?source=related_link\">",
"      Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7400?source=related_link\">",
"      Diffusing capacity for carbon monoxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12789?source=related_link\">",
"      Enhancing patient adherence to asthma therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7416?source=related_link\">",
"      Exhaled nitric oxide analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=related_link\">",
"      Hoarseness in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13735?source=related_link\">",
"      Identifying patients at risk for fatal asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16567?source=related_link\">",
"      Paradoxical vocal cord motion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36278?source=related_link\">",
"      Severe asthma: Evidence for heterogeneity of the disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35353?source=related_link\">",
"      Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2532?source=related_link\">",
"      Tropical filarial pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_49_14106="Hematologic manifestations of systemic lupus erythematosus in adults";
var content_f13_49_14106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematologic manifestations of systemic lupus erythematosus in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14106/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14106/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14106/contributors\">",
"     Nancy Berliner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14106/contributors\">",
"     David S Pisetsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/49/14106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/49/14106/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/49/14106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the formed elements of the blood, and of the clotting, fibrinolytic, and related systems, are very common in systemic lupus erythematosus (SLE). The major hematologic manifestations of SLE are anemia, leukopenia, thrombocytopenia, and the antiphospholipid syndrome (APS). This topic review will provide an overview of these problems, most of which will be discussed in more detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is a frequent occurrence in SLE, affecting most patients at some time in the course of their disease. Multiple mechanisms contribute to the development of anemia, including inflammation, renal insufficiency, blood loss, dietary insufficiency, medications, hemolysis, infection, hypersplenism, myelofibrosis, myelodysplasia, and aplastic anemia that is suspected to have an autoimmune pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/1-8\">",
"     1-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anemia of chronic inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frequent cause of anemia in SLE is suppressed erythropoiesis from chronic inflammation (anemia of chronic disease or anemia of chronic inflammation) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/4\">",
"     4",
"    </a>",
"    ]. The anemia is normocytic and normochromic with a relatively low reticulocyte count. Although serum iron levels may be reduced, bone marrow iron stores are adequate, and the serum ferritin concentration is elevated. The major mediator of the anemia of chronic inflammation is hepcidin, a central regulator of iron homeostasis that inhibits the release of iron from macrophages and iron absorption in the small intestine. This results in iron-limited hematopoiesis. The mechanisms by which this anemia is produced by chronic inflammatory diseases are further discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in other chronic illnesses, serum erythropoietin levels may be inappropriately low for the degree of anemia. However, some of the apparent reduction in serum erythropoietin may be spurious; autoantibodies to erythropoietin may interfere with commercial laboratory testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of either symptoms attributable to anemia (eg, dyspnea on exertion, easy fatigability) or renal insufficiency (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Renal insufficiency'",
"    </a>",
"    below), anemia of chronic inflammation does not require specific treatment.",
"   </p>",
"   <p>",
"    Patients with symptoms due to anemia of chronic inflammation and without another definite indication for glucocorticoid or other immunosuppressive therapy may be given a trial of an agent that promotes erythropoiesis. Two such agents are available in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       Epoetin alfa",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      ). Treatment should be started at 80 to 120",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per week (usually as two to three injections per week). The patient should be reassessed after one month, and the dose should be increased monthly until the hemoglobin level is maintained at &ge;11",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       Darbepoetin alfa",
"      </a>",
"      , a unique molecule that stimulates erythropoiesis with a longer half-life than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      . A typical dose of darbepoetin alfa for adults is 0.45",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      once a week.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study that assessed the response to erythropoietin in patients with SLE and anemia of chronic inflammation, 58 percent had an adequate response to erythropoietin supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who are symptomatically anemic have signs of active inflammation, and do not respond to an agent that promotes erythropoiesis often improve when glucocorticoids are used in high doses (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent in divided doses). If, after approximately one month of treatment, the response is unsatisfactory (eg, hemoglobin still &lt;11",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    the dose of glucocorticoids should be rapidly reduced and discontinued if there is no other indication for their use. If there is a response, the dose should be tapered as rapidly as to possible to the lowest dose that maintains the improvement. Immunosuppressive agents also may help but carry a risk of further bone marrow suppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inappropriately low level of erythropoietin is a hallmark of anemia due to renal insufficiency. The primary cause of anemia in this setting is typically deficient production of erythropoietin by the diseased kidneys. In the patient with SLE, anemia, and renal insufficiency who does not have other evidence of active inflammation, administration of erythropoiesis-stimulating agents may be indicated when the anemia is causing symptoms or the hemoglobin concentration is &lt;11",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    rationale for treating anemia due to chronic renal disease prior to initiation of renal replacement therapy (dialysis or transplantation) is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia may reflect acute or chronic blood loss from the gastrointestinal tract, usually secondary to medications (nonsteroidal antiinflammatory drugs or steroids), or may be due to excessive menstrual bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .) Iron deficiency anemia is not uncommon, especially among teenagers or young women. Long-term anemia of chronic inflammation can also lead to iron deficiency, since, as mentioned earlier (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Anemia of chronic inflammation'",
"    </a>",
"    above), hepcidin, the key inducer of the anemia of chronic inflammation, inhibits iron absorption from the gastrointestinal tract.",
"   </p>",
"   <p>",
"    Pulmonary hemorrhage is a rare cause of anemia in SLE. Not all patients have hemoptysis. Other symptoms of alveolar hemorrhage are dyspnea and cough. The presence of alveolar infiltrates on a chest radiograph or ground-glass opacities on chest CT are suggestive of alveolar hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link&amp;anchor=H27#H27\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in adults\", section on 'Pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Red cell aplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell aplasia, probably due to antibodies directed against either erythropoietin or bone marrow erythroblasts, has been observed, although it is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/5,6,10\">",
"     5,6,10",
"    </a>",
"    ]. This form of anemia usually responds to steroids, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    have been successfully employed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=see_link\">",
"     \"Acquired pure red cell aplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even rarer are isolated case reports of aplastic anemia, presumably mediated by autoantibodies against bone marrow precursors; immunosuppressive therapy also may be effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, bone marrow suppression can also be induced by medications, including antimalarials and immunosuppressive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Autoimmune hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt autoimmune hemolytic anemia (AIHA), characterized by an elevated reticulocyte count, low haptoglobin levels, increased indirect bilirubin concentration, and a positive direct Coombs' test, has been noted in up to 10 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/2-4,8,14\">",
"     2-4,8,14",
"    </a>",
"    ]. The presence of hemolytic anemia may be associated with other manifestations of severe disease such as renal disease, seizures, and serositis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other patients have a positive Coombs' test without evidence of overt hemolysis. The presence of both immunoglobulin and complement on the red cell is usually associated with some degree of hemolysis, while the presence of complement alone (eg, C3",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C4) is often not associated with hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The antibodies are \"warm,\" IgG, and directed against Rh determinants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"    </a>",
"    .) IgM mediated cold agglutinin hemolysis is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIHA responds to steroids (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent in divided doses) in 75 to 96 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Once the hematocrit begins to rise and the reticulocyte count falls, steroids can be rapidly tapered. If there is no response, one can consider pulse steroids (eg, 1000 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    intravenously daily for three days) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/15\">",
"     15",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (up to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/17\">",
"     17",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (up to 2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/18\">",
"     18",
"    </a>",
"    ], or splenectomy. Success rates for splenectomy as high as 60 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/19\">",
"     19",
"    </a>",
"    ], although others have found no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other anecdotally described approaches to patients with refractory AIHA include intravenous immune globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/18\">",
"     18",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    (in doses of 600 to 800",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/21-23\">",
"     21-23",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/24\">",
"     24",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Microangiopathic hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lupus has also been associated with a thrombotic microangiopathic hemolytic anemia (TMA) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/26\">",
"     26",
"    </a>",
"    ] as manifested by a peripheral blood smear showing schistocytes and elevated serum levels of lactate dehydrogenase (LDH) and bilirubin (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ). Many affected patients also have thrombocytopenia, kidney involvement, fever, and neurologic symptoms. This pentad of features is compatible with a diagnosis of thrombotic thrombocytopenic purpura (TTP). However, the pathogenesis of thrombotic microangiopathy in these patients is likely heterogeneous, as it may reflect vasculitis or antiphospholipid syndrome as well [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the occurrence of both SLE and TTP in an individual patient is a coincidence or represents a true association is an unsettled question.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 1998 review of the world literature, only 40 such cases were found [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent retrospective study of renal biopsies of 257 patients with SLE identified four cases with compatible clinical features and histologic evidence of TTP [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large study of patients with TMA in association with connective tissue disease examined clinical parameters of the disease in the context of assessment of ADAMTS13 activity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/27\">",
"       27",
"      </a>",
"      ]. Most of the 127 patients with TMA and a connective tissue disease had depressed ADAMTS13 activity. Severe deficiency was found in only 16 percent of those with associated CTD, as compared with 70 percent of the 64 patients with idiopathic TTP. Very low ADAMTS13 levels were associated with inhibitory antibodies directed against the enzyme. Clinical response rates in patients with SLE were comparable to patients with idiopathic TTP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other patients with microangiopathic red cell destruction do not have fever or neurologic disease, producing a pattern of hemolytic-uremic syndrome. The pathogenesis of this syndrome is not completely understood. In one report of four patients plus 24 others identified from a literature review, antiphospholipid antibodies (aPL) were searched for in eight and found in five [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of aPL in SLE patients with severe hemolytic anemia, renal dysfunction, and central nervous system involvement has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Hematologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 28 reported patients, those treated with plasma infusions or plasmapheresis, glucocorticoids alone, or no therapy had mortality rates of 25, 50, and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/26\">",
"     26",
"    </a>",
"    ]. However, in another series of 15 patients with SLE and microangiopathic hemolytic anemia, all responded to treatment with high-dose glucocorticoids, and none were treated with plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/32\">",
"     32",
"    </a>",
"    ]. In a retrospective study cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/27\">",
"     27",
"    </a>",
"    ] in which 70 percent of patients with SLE and TMA underwent plasma exchange, the response rate of 74 percent was comparable to that observed in patients with idiopathic TTP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83523360\">",
"    <span class=\"h4\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SLE, severe microangiopathic hemolytic anemia, and other major organ dysfunction should be treated with plasmapheresis and plasma infusion as in other cases of thrombotic thrombocytopenic purpura or the hemolytic-uremic syndrome. Those with less severe disease may be treated with high-dose glucocorticoids and observed carefully with the addition of plasmapheresis should they deteriorate or fail to improve with steroid treatment alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Available testing for ADAMTS13 activity has a turnaround time that is too long to be useful in initial treatment decision making. However, anticipated development of rapid assays for ADAMTS13 activity may help to distinguish patients with TTP from those with other etiologies for their TMA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LEUKOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia is common in SLE and usually reflects disease activity. A white blood cell count of less than",
"    <span class=\"nowrap\">",
"     4500/microL",
"    </span>",
"    has been noted in approximately 50 percent of patients, especially those with active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], while lymphocytopenia occurs in approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/3\">",
"     3",
"    </a>",
"    ]. In comparison, a white blood cell count below",
"    <span class=\"nowrap\">",
"     4000/microL",
"    </span>",
"    (an American College of Rheumatology criterion for SLE) occurs in only 15 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]. Neutropenia, lymphocytopenia, and decreased circulating eosinophils and basophils may all contribute to leukopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia in patients with SLE can result from immune mechanisms, medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ), bone marrow dysfunction, or hypersplenism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/3,4,33,34\">",
"     3,4,33,34",
"    </a>",
"    ]. Other clinical features that may be associated with moderate to severe neutropenia (absolute neutrophils",
"    <span class=\"nowrap\">",
"     &lt;1000/microL)",
"    </span>",
"    include infection, anemia, thrombocytopenia, and a history of neuropsychiatric involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Functional defects of neutrophils have also been noted. They are thought to be induced by immune abnormalities (eg, immune complexes, inhibition of complement-derived chemotactic factors)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medications (eg, glucocorticoids) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lymphocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytopenia (lymphocytes less than",
"    <span class=\"nowrap\">",
"     1500/microL),",
"    </span>",
"    especially involving suppressor T cells, has been observed in 20 to 75 percent of patients, particularly during active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/1-3,37,38\">",
"     1-3,37,38",
"    </a>",
"    ]. This finding is strongly associated with IgM, cold reactive, complement fixing, and presumably cytotoxic antilymphocyte antibodies; such antibodies were noted in 26 of 29 patients with SLE, and the antibody titer correlated directly with the degree of lymphopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential mechanism of lymphopenia is increased apoptosis as reflected by increased expression of Fas antigen on T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Decreased eosinophils and basophils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid therapy may result in low absolute eosinophil and monocyte counts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of basophils may also be decreased in SLE, particularly during active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/42\">",
"     42",
"    </a>",
"    ]. Basophil degranulation with release of platelet activating factor and other mediators may play a role in immune complex deposition and vascular permeability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia in SLE rarely needs treatment. An exception is the patient with neutropenia and recurrent pyogenic infections. One problem is the toxicity of the usual therapies.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    (10 to 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    can raise the white blood cell count but can also result in an increased risk of infections; immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have the potential to cause worsening of the leukopenia via bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cautious use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , with careful monitoring of the white blood cell count, may be considered in this setting.",
"   </p>",
"   <p>",
"    Therapies for leukopenia used in other settings may result in significant adverse results when applied to patients with SLE. As an example, one study of nine patients with neutropenia and refractory infections found that treatment with recombinant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) increased the polymorphonuclear cell count but also caused a disease flare in three patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/44\">",
"     44",
"    </a>",
"    ]. Leukocytoclastic vasculitis has also developed in some patients; thus, it is recommended that the minimum amount of G-CSF be used in order to maintain the peripheral neutrophil count",
"    <span class=\"nowrap\">",
"     &ge;1000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LEUKOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis (mostly granulocytes) can occur in SLE. When present, it is usually due to infection or the use of high doses of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/43\">",
"     43",
"    </a>",
"    ], but it may occur during acute exacerbations of SLE. A shift of granulocytes to more immature forms (a \"left\" shift) suggests infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild thrombocytopenia (platelet counts between 100,000 and",
"    <span class=\"nowrap\">",
"     150,000/microL)",
"    </span>",
"    has been noted in 25 to 50 percent of patients, while counts of less than",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    occur in only 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/1,3,4,33\">",
"     1,3,4,33",
"    </a>",
"    ]. There are several potential causes of thrombocytopenia in patients with SLE. Immune mediated platelet destruction is most often the cause, but platelet consumption may also occur in association with microangiopathic hemolytic anemia (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Microangiopathic hemolytic anemia'",
"    </a>",
"    above) or may be due to impaired platelet production as a result of the use of cytotoxic, immunosuppressive, or other drugs (",
"    <a class=\"graphic graphic_table graphicRef73618 \" href=\"UTD.htm?36/3/36924\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major mechanism is immunoglobulin binding to platelets followed by phagocytosis in the spleen, as in immune thrombocytopenia (ITP) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/47\">",
"     47",
"    </a>",
"    ]. Membrane glycoproteins (GP) are most often the target of such antibodies (eg, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa),",
"    </span>",
"    but anti-HLA specificity also occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antigen-dependent B cell development in lymphoid tissues is influenced by binding of CD40 on B cells to CD40-ligand on activated T cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    .) The finding of autoantibodies to CD40-ligand in patients with SLE, APS, and ITP, but not in the serum of healthy blood donors, suggests that interference with T cell and B cell interaction may play a role in the development of thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other important mechanisms in selected patients include bone marrow suppression by immunosuppressive drugs (other than glucocorticoids), increased consumption due to a thrombotic microangiopathy (thrombotic thrombocytopenic purpura [TTP]) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/26\">",
"     26",
"    </a>",
"    ], the antiphospholipid syndrome, or antibodies that block the thrombopoietin receptor on megakaryocytes or their precursors. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Antibodies to clotting factors and phospholipids'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H35#H35\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Bone marrow examination'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=see_link&amp;anchor=H5#H5\">",
"     \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\", section on 'Amegakaryocytic thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ITP may be the first sign of SLE, followed by other symptoms as distant as many years later. It has been estimated that 3 to 15 percent of patients with apparently isolated ITP go on to develop SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/50\">",
"     50",
"    </a>",
"    ]. Evans syndrome (ie, both autoimmune thrombocytopenia and autoimmune hemolytic anemia) also may precede the onset of SLE. Severe bleeding from thrombocytopenia is only experienced by a minority of patients; however, SLE patients with thrombocytopenia are more likely to have associated significant organ damage, such as that of the heart, the kidneys, or the CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Splenectomy in ITP was originally thought to predispose to the development of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/52\">",
"     52",
"    </a>",
"    ]. However, this hypothesis was refuted in subsequent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet counts between",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     20,000/microL",
"    </span>",
"    rarely cause more than a prolonged bleeding time, while counts of less than",
"    <span class=\"nowrap\">",
"     20,000/microL",
"    </span>",
"    may be associated with (and may account for) petechiae, purpura, ecchymoses, epistaxis, gingival, and other clinical bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of thrombocytopenia is usually recommended for symptomatic patients with counts of less than",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and for all patients with counts of less than",
"    <span class=\"nowrap\">",
"     20,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    The treatment of ITP in SLE is the same as that in patients without lupus and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reviewed briefly, the mainstay of treatment is glucocorticoid therapy. Older studies used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in divided doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, treatment with four to eight cycles of oral high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (40 mg per day for four days) at intervals of two weeks to four weeks may result in similar remission rates and better long-term responses than those observed in historical controls treated with daily prednisone; a direct comparison of pulse dexamethasone and prednisone is underway [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients respond to glucocorticoid therapy within one to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/57\">",
"     57",
"    </a>",
"    ]. If there is no significant increase in the platelet count within one to three weeks or if side effects are intolerable, the following options may be considered. The order in which they are used depends in part upon the severity of the thrombocytopenia and the presence or absence of other manifestations of SLE.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      (0.5 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      , given as daily oral or intravenous pulse therapy. Intravenous pulse cyclophosphamide is preferred in patients who also have severe active lupus nephritis. In one report of six such patients, all had normal platelet counts within 2 to 18 weeks after the onset of pulse cyclophosphamide [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous immune globulin, which is very effective and may be preferred to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      when a rapid rise in platelet count is necessary (as in the patient who is actively bleeding or requires emergent surgery) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil, which may be useful in the patient refractory to other medical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      , which has been used to treat ITP in patients without SLE who were refractory to other treatments. This B lymphocyte depleting approach may be beneficial for other manifestations of lupus [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/25\">",
"       25",
"      </a>",
"      ]. A rituximab regimen is 375",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV approximately once weekly for 4 consecutive weeks, supplemented by 100 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      IV (or 50 to 100 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      orally) given as premedication together with an antihistamine just before infusion of rituximab [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/61\">",
"       61",
"      </a>",
"      ]. The role of rituximab in the first line therapy of ITP is under investigation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy can raise the platelet count, but it does not reliably produce a durable remission of thrombocytopenia. Relapse following splenectomy may occur and has been noted at varying times from 1 to 54 months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest observational series, splenectomy was performed in 25 patients with SLE seen from 1975 to 2001 at the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/63\">",
"     63",
"    </a>",
"    ]. After a median follow up of 6.6 years, 16 patients had a complete or partial response; eight of these subsequently required medical therapy. Nine patients relapsed, but five subsequently responded to medical therapy. However, after a median follow up of 9.5 years, 9 of the 25 patients had died (only one as a result of bleeding complications). These observations suggest a favorable effect of splenectomy, at least in one highly selected group of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Thrombocytopenia following splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent thrombocytopenia after splenectomy may subsequently respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , intravenous immunoglobulin, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/23,63,64\">",
"     23,63,64",
"    </a>",
"    ]. If possible, splenectomy should be preceded by immunization with pneumococcal vaccine to reduce the risk of pneumococcal sepsis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       Danazol",
"      </a>",
"      (400 to 800",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. As an example, six of six patients who were refractory to other therapies responded to danazol (200 mg four times daily) within six weeks; this benefit occurred without a change in platelet-bound IgG antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/65\">",
"       65",
"      </a>",
"      ]. The dose could be tapered without relapse in five of the six patients. In another series of 34 patients, excellent long-term results were achieved with danazol (increasing doses from 200 to 1200 mg per day) for at least 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       Vincristine",
"      </a>",
"      . Successful use of vincristine has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/68\">",
"       68",
"      </a>",
"      ]. When used for ITP, a common regimen for vincristine is 2 mg IV weekly for several weeks. Side effects include peripheral neuropathy, which may be persistent, and constipation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     THROMBOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytosis is a less frequent finding in those with SLE. As an example, among 465 patients with SLE, 17 (3.7 percent) were found to have thrombocytosis (platelet",
"    <span class=\"nowrap\">",
"     &ge;400,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </span>",
"    Three of these patients had one or more of the following features on peripheral blood smear: Howell-Jolly bodies, spherocytes, and target cells. Ultrasound, CT, and liver-spleen scintigraphy failed to demonstrate a spleen. All three patients had aPL [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/69\">",
"     69",
"    </a>",
"    ]. These observations suggest that autosplenectomy may occur in patients with SLE, perhaps mediated by aPL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PANCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although peripheral destruction of red cells, leukocytes, and platelets may occur together and lead to clinically significant pancytopenia, depression of all three cell lines also suggests bone marrow failure, as in the case in aplastic anemia. Thus, bone marrow examination is the most important diagnostic test to perform. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Causes of marrow failure include drugs and coincidental diseases including the acute leukemias, large granular lymphocyte leukemia, the myelodysplastic syndromes, marrow replacement by fibrosis or tumor, severe megaloblastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), and overwhelming infection. In addition, unexplained cytopenia can be associated with bone marrow necrosis, dysplasia, and distortion of the bone marrow architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\", section on 'Secondary forms of myelofibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with SLE, an unusual cause of pancytopenia is the macrophage activation syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical characteristics of 12 patients with SLE-associated macrophage activation syndrome included [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever &mdash; 100 percent",
"     </li>",
"     <li>",
"      Weight loss &mdash; 80 percent",
"     </li>",
"     <li>",
"      Arthritis &mdash; 50 percent",
"     </li>",
"     <li>",
"      Pericarditis &mdash; 42 percent",
"     </li>",
"     <li>",
"      Rash &mdash; 66 percent",
"     </li>",
"     <li>",
"      Myocarditis &mdash; 33 percent",
"     </li>",
"     <li>",
"      Nephritis &mdash; 33 percent",
"     </li>",
"     <li>",
"      Splenomegaly &mdash; 27 percent",
"     </li>",
"     <li>",
"      Hepatomegaly &mdash;13 percent",
"     </li>",
"     <li>",
"      Lymphadenopathy &mdash; 73 percent",
"     </li>",
"     <li>",
"      Anemia &mdash; 100 percent",
"     </li>",
"     <li>",
"      Leukopenia &mdash; 87 percent",
"     </li>",
"     <li>",
"      Hyperferritinemia &mdash; 100 percent",
"     </li>",
"     <li>",
"      Anti-DNA antibodies &mdash; 80 percent",
"     </li>",
"     <li>",
"      Low CRP (&lt;30",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      &mdash; 90 percent",
"     </li>",
"     <li>",
"      Hypocomplementemia &mdash; 60 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The demonstration of hemophagocytosis in the bone marrow or in material obtained from peripheral lymph nodes is a characteristic finding.",
"   </p>",
"   <p>",
"    The few reported cases of macrophage activation syndrome in patients with SLE have usually responded to treatment with glucocorticoids and immunosuppressive agents. Optimal treatment is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LYMPHADENOPATHY AND SPLENOMEGALY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enlargement of lymph nodes occurs in approximately 50 percent of patients with SLE. The nodes are typically soft, nontender, discrete, varying in size from 0.5 to several centimeters, and usually detected in the cervical, axillary and inguinal areas. Lymphadenopathy is more frequently noted at the onset of disease or in association with an exacerbation. Biopsies reveal areas of follicular hyperplasia and necrosis; the appearance of hematoxylin bodies is highly suggestive of SLE, although unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymph node enlargement can also be due to infection or a lymphoproliferative disease in SLE. When infections are present, the enlarged nodes are more likely to be tender.",
"   </p>",
"   <p>",
"    Prominent lymphadenopathy may also be a manifestation of angioimmunoblastic T cell lymphoma. This disorder has other clinical features (arthritis, Coombs-positive hemolytic anemia, skin rash, fever, and weight loss) that are suggestive of systemic lupus erythematosus or systemic onset juvenile idiopathic arthritis (Still's disease). This type of T cell lymphoma is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enlargement of the spleen occurs in 10 to 46 percent of patients, particularly during active disease. Splenomegaly is not necessarily associated with a cytopenia. Pathologic examination of the spleen reveals an onion skin appearance of the splenic arteries, a lesion that is thought to represent healed vasculitis.",
"   </p>",
"   <p>",
"    In view of the frequent presence of lymphadenopathy and splenomegaly in SLE, the possibility of a lymphoproliferative malignancy may be considered. The risk of non-Hodgkin lymphoma appears to be increased four- to fivefold in patients with lupus. The studies that provide this estimate of the relative risk of lymphoma and issues related to the risk of other malignancies is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Is cancer risk increased?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another group at risk for lymphoproliferative disorders is patients treated with prolonged oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy (which is unusual in SLE) who are also at increased risk for bladder and other malignancies. Pulse intravenous cyclophosphamide appears to have eliminated the risk of bladder cancer. The long-term risk of non-bladder malignancy with intravenous pulse dosing is uncertain, but no association has yet been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A lymph node biopsy may be warranted when the degree of lymphadenopathy is out of proportion to the activity of the lupus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ANTIBODIES TO CLOTTING FACTORS AND PHOSPHOLIPIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to a number of clotting factors, including VIII, IX, XI, XII, and XIII, have been noted in patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/1,2,33\">",
"     1,2,33",
"    </a>",
"    ]. These antibodies may not only cause abnormalities of in vitro coagulation tests but may also cause bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link\">",
"     \"Acquired inhibitors of coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Much more common are aPL, the presence of which has been associated with a prolongation of the partial thromboplastin time (lupus anticoagulant activity) and an increased risk of arterial and venous thrombosis, thrombocytopenia, and fetal loss [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Antibodies to other phospholipids and to phospholipid binding proteins (eg, anticardiolipin antibodies) in moderate or high levels may also be associated with these clinical phenomena. When aPL occur in association with one or more of these clinical features in a patient with SLE, it suggests the presence of the APS. A more detailed discussion of this disorder is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased prevalence of aPL in patients with SLE following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was noted in a single retrospective study that compared 177 cyclophosphamide-treated SLE patients to 203 patients with SLE never treated with this alkylating agent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/75\">",
"     75",
"    </a>",
"    ]. Seroconversion occurred at a higher rate in the cyclophosphamide-treated patients (19 versus 1 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ERYTHROCYTE SEDIMENTATION RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although acute phase reactants, such as the erythrocyte sedimentation rate (ESR) and serum C-reactive protein levels, are less reliable markers of disease activity in lupus than they are in many other inflammatory conditions, including rheumatoid arthritis and polymyalgia rheumatica [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/76\">",
"     76",
"    </a>",
"    ], elevated levels of the ESR may be associated with activity and accumulated damage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/49/14106/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=see_link\">",
"       \"Patient information: Anemia of chronic disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268716918\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia is a frequent occurrence in SLE, affecting most patients at some time in the course of their disease. Multiple mechanisms contribute to the development of anemia, including inflammation, renal insufficiency, blood loss, dietary insufficiency, medications, hemolysis, infection, hypersplenism, myelofibrosis, myelodysplasia, and aplastic anemia that is suspected to have an autoimmune pathogenesis. Treatment of anemia differs depending upon the mechanism. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anemia of chronic inflammation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Renal insufficiency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Iron deficiency anemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Red cell aplasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Autoimmune hemolytic anemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Microangiopathic hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leukopenia is common in SLE and usually reflects disease activity, although it may also result from certain medications, particularly immunosuppressive drugs. Decreases in different cell lines may occur independently of each other and may result from different mechanisms. Leukopenia in SLE rarely needs treatment, except when neutropenia results in recurrent pyogenic infections. Leukocytosis (mostly granulocytes) is usually due to infection or the use of high doses of glucocorticoids. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Leukopenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Neutropenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Lymphocytopenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Decreased eosinophils and basophils'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Recommendations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Leukocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild thrombocytopenia is common in SLE; more severe thrombocytopenia occurs in only 10 percent. Immune thrombocytopenia (ITP) may be the first sign of SLE, followed by other symptoms as distant as many years later. Potential causes of thrombocytopenia in SLE include immune mediated platelet destruction, which is the most common, and platelet consumption, associated with microangiopathic hemolytic anemia or due to impaired platelet production from medications (",
"      <a class=\"graphic graphic_table graphicRef73618 \" href=\"UTD.htm?36/3/36924\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Thrombocytopenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of thrombocytopenia is usually recommended for symptomatic patients with counts of less than",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      and for all patients with counts of less than",
"      <span class=\"nowrap\">",
"       20,000/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Medical therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pancytopenia may result either from peripheral destruction of red cells, leukocytes, and platelets together or from bone marrow failure. Thus, in patients with pancytopenia, bone marrow examination is the most important diagnostic test. There are a number of potential causes to consider such as drugs, various other diseases, and bone marrow abnormalities; an uncommon cause is the macrophage activation syndrome. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Pancytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphadenopathy occurs in approximately 50 percent of patients with SLE, more frequently at the onset of disease or in association with an exacerbation. Splenomegaly may also be present, particularly during active disease. A lymph node biopsy may be warranted when the degree of lymphadenopathy is out of proportion to the activity of the lupus. Other causes include infection or a lymphoproliferative disorder, such as non-Hodgkin lymphoma or angioimmunoblastic T cell lymphoma. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Lymphadenopathy and splenomegaly'",
"      </a>",
"      above.) Lymphadenopathy due to SLE does not require treatment, but enlarged nodes typically melt away on steroids. Lymphadenopathy in a patient on moderate or greater doses of glucocorticoids should increase suspicion regarding infection or malignancy.",
"     </li>",
"     <li>",
"      Antibodies to a number of clotting factors, including VIII, IX, XI, XII, and XIII, have been noted in rare patients with SLE, which may cause abnormalities of in vitro coagulation tests and sometimes bleeding. Much more common are antiphospholipid antibodies, the presence of which has been associated with a prolongation of the partial thromboplastin time (lupus anticoagulant activity) and an increased risk of arterial and venous thrombosis, thrombocytopenia, and fetal loss. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Antibodies to clotting factors and phospholipids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated levels of the erythrocyte sedimentation rate (ESR) may be associated with disease activity, but the ESR is a less reliable marker of disease activity in lupus than in many other inflammatory conditions. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Erythrocyte sedimentation rate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Laurence J, Wong JE, Nachman R. The cellular hematology of systemic lupus erythematosus. In: Systemic Lupus Erythematosus, 2nd, Lahita RG (Ed), Churchill Livingstone, New York 1992.",
"    </li>",
"    <li>",
"     Shoenfeld Y, Ehrenfeld M. Hematologic manifestations. In: The Clinical Management of Systemic Lupus Erythematosus, 2nd, Schur PH (Ed), Lippincott, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/3\">",
"      Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991; 80:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/4\">",
"      Keeling DM, Isenberg DA. Haematological manifestations of systemic lupus erythematosus. Blood Rev 1993; 7:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/5\">",
"      Liu H, Ozaki K, Matsuzaki Y, et al. Suppression of haematopoiesis by IgG autoantibodies from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995; 100:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/6\">",
"      Habib GS, Saliba WR, Froom P. Pure red cell aplasia and lupus. Semin Arthritis Rheum 2002; 31:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/7\">",
"      Voulgarelis M, Kokori SI, Ioannidis JP, et al. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis 2000; 59:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/8\">",
"      Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 2006; 65:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/9\">",
"      Schett G, Firbas U, F&uuml;reder W, et al. Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/10\">",
"      Hara A, Wada T, Kitajima S, et al. Combined pure red cell aplasia and autoimmune hemolytic anemia in systemic lupus erythematosus with anti-erythropoietin autoantibodies. Am J Hematol 2008; 83:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/11\">",
"      Winkler A, Jackson RW, Kay DS, et al. High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia. Arthritis Rheum 1988; 31:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/12\">",
"      Brooks BJ Jr, Broxmeyer HE, Bryan CF, Leech SH. Serum inhibitor in systemic lupus erythematosus associated with aplastic anemia. Arch Intern Med 1984; 144:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/13\">",
"      Roffe C, Cahill MR, Samanta A, et al. Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism? Br J Rheumatol 1991; 30:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/14\">",
"      Jeffries M, Hamadeh F, Aberle T, et al. Haemolytic anaemia in a multi-ethnic cohort of lupus patients: a clinical and serological perspective. Lupus 2008; 17:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/15\">",
"      Jacob HS. Pulse steroids in hematologic diseases. Hosp Pract (Off Ed) 1985; 20:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/16\">",
"      Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006; 15:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/17\">",
"      Corley CC Jr, Lessner HE, Larsen WE. Azathioprine therapy of \"autoimmune\" diseases. Am J Med 1966; 41:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/18\">",
"      Murphy S, LoBuglio AF. Drug therapy of autoimmune hemolytic anemia. Semin Hematol 1976; 13:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/19\">",
"      Coon WW. Splenectomy for cytopenias associated with systemic lupus erythematosus. Am J Surg 1988; 155:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/20\">",
"      Rivero SJ, Alger M, Alarc&oacute;n-Segovia D. Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal. Arch Intern Med 1979; 139:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/21\">",
"      Chan AC, Sack K. Danazol therapy in autoimmune hemolytic anemia associated with systemic lupus erythematosus. J Rheumatol 1991; 18:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/22\">",
"      Ahn YS, Harrington WJ, Mylvaganam R, et al. Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 1985; 102:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/23\">",
"      Letchumanan P, Thumboo J. Danazol in the treatment of systemic lupus erythematosus: a qualitative systematic review. Semin Arthritis Rheum 2011; 40:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/24\">",
"      Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003; 12:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/25\">",
"      Looney RJ. B cell-targeted therapy in diseases other than rheumatoid arthritis. J Rheumatol Suppl 2005; 73:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/26\">",
"      Nesher G, Hanna VE, Moore TL, et al. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994; 24:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/27\">",
"      Matsuyama T, Kuwana M, Matsumoto M, et al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 2009; 102:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/28\">",
"      George JN, Vesely SK, James JA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J 2007; 100:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/29\">",
"      Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/30\">",
"      Manadan AM, Harris C, Schwartz MM, Block JA. The frequency of thrombotic thrombocytopenic purpura in patients with systemic lupus erythematosus undergoing kidney biopsy. J Rheumatol 2003; 30:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/31\">",
"      Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford) 2003; 42:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/32\">",
"      Dold S, Singh R, Sarwar H, et al. Frequency of microangiopathic hemolytic anemia in patients with systemic lupus erythematosus exacerbation: Distinction from thrombotic thrombocytopenic purpura, prognosis, and outcome. Arthritis Rheum 2005; 53:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/33\">",
"      Budman DR, Steinberg AD. Hematologic aspects of systemic lupus erythematosus. Current concepts. Ann Intern Med 1977; 86:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/34\">",
"      Mart&iacute;nez-Ba&ntilde;os D, Crisp&iacute;n JC, Lazo-Langner A, S&aacute;nchez-Guerrero J. Moderate and severe neutropenia in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2006; 45:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/35\">",
"      Perez HD, Lipton M, Goldstein IM. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest 1978; 62:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/36\">",
"      Abramson SB, Given WP, Edelson HS, Weissmann G. Neutrophil aggregation induced by sera from patients with active systemic lupus erythematosus. Arthritis Rheum 1983; 26:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/37\">",
"      Rivero SJ, D&iacute;az-Jouanen E, Alarc&oacute;n-Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 1978; 21:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/38\">",
"      Vil&aacute; LM, Alarc&oacute;n GS, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum 2006; 55:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/39\">",
"      Winfield JB, Winchester RJ, Kunkel HG. Association of cold-reactive antilymphocyte antibodies with lymphopenia in systemic lupus erythematosus. Arthritis Rheum 1975; 18:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/40\">",
"      Amasaki Y, Kobayashi S, Takeda T, et al. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin Exp Immunol 1995; 99:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/41\">",
"      Isenberg DA, Patterson KG, Todd-Pokropek A, et al. Haematological aspects of systemic lupus erythematosus: a reappraisal using automated methods. Acta Haematol 1982; 67:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/42\">",
"      Camussi G, Tetta C, Coda R, Benveniste J. Release of platelet-activating factor in human pathology. I. Evidence for the occurrence of basophil degranulation and release of platelet-activating factor in systemic lupus erythematosus. Lab Invest 1981; 44:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/43\">",
"      Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993; 119:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/44\">",
"      Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997; 24:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/45\">",
"      Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum 1999; 29:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/46\">",
"      Starkebaum G. Chronic neutropenia associated with autoimmune disease. Semin Hematol 2002; 39:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/47\">",
"      Pujol M, Ribera A, Vilardell M, et al. High prevalence of platelet autoantibodies in patients with systemic lupus erythematosus. Br J Haematol 1995; 89:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/48\">",
"      Michel M, Lee K, Piette JC, et al. Platelet autoantibodies and lupus-associated thrombocytopenia. Br J Haematol 2002; 119:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/49\">",
"      Nakamura M, Tanaka Y, Satoh T, et al. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with thrombocytopenia but not thromboembolism. Rheumatology (Oxford) 2006; 45:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/50\">",
"      Karpatkin S. Autoimmune thrombocytopenic purpura. Blood 1980; 56:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/51\">",
"      Ziakas PD, Giannouli S, Zintzaras E, et al. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005; 64:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/52\">",
"      DAMESHEK W, REEVES WH. Exacerbation of lupus erythematosus following splenectomy in idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia. Am J Med 1956; 21:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/53\">",
"      BEST WR, DARLING DR. A critical look at the splenectomy-S.L.E. controversy. Med Clin North Am 1962; 46:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/54\">",
"      George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/55\">",
"      Blanchette V, Freedman J, Garvey B. Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol 1998; 35:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/56\">",
"      Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/57\">",
"      Goebel KM, Gassel WD, Goebel FD. Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. Scand J Haematol 1973; 10:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/58\">",
"      Boumpas DT, Barez S, Klippel JH, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990; 112:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/59\">",
"      Maier WP, Gordon DS, Howard RF, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 1990; 33:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/60\">",
"      Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003; 12:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/61\">",
"      Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005; 78:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/62\">",
"      Hall S, McCormick JL Jr, Greipp PR, et al. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med 1985; 102:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/63\">",
"      You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg 2004; 240:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/64\">",
"      Vesely SK, Perdue JJ, Rizvi MA, et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med 2004; 140:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/65\">",
"      West SG, Johnson SC. Danazol for the treatment of refractory autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1988; 108:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/66\">",
"      Cervera H, Jara LJ, Pizarro S, et al. Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans' syndrome. J Rheumatol 1995; 22:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/67\">",
"      Avi&ntilde;a-Zubieta JA, Galindo-Rodr&igrave;guez G, Robledo I, et al. Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus. Lupus 2003; 12:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/68\">",
"      Ahn YS, Harrington WJ, Seelman RC, Eytel CS. Vincristine therapy of idiopathic and secondary thrombocytopenias. N Engl J Med 1974; 291:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/69\">",
"      Castellino G, Govoni M, Prandini N, et al. Thrombocytosis in systemic lupus erythematosus: a possible clue to autosplenectomy? J Rheumatol 2007; 34:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/70\">",
"      Voulgarelis M, Giannouli S, Tasidou A, et al. Bone marrow histological findings in systemic lupus erythematosus with hematologic abnormalities: a clinicopathological study. Am J Hematol 2006; 81:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/71\">",
"      Wanitpongpun C, Teawtrakul N, Mahakkanukrauh A, et al. Bone marrow abnormalities in systemic lupus erythematosus with peripheral cytopenia. Clin Exp Rheumatol 2012; 30:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/72\">",
"      Lambotte O, Khellaf M, Harmouche H, et al. Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine (Baltimore) 2006; 85:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/73\">",
"      Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/74\">",
"      Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/75\">",
"      Vlachoyiannopoulos PG, Toya SP, Katsifis G, et al. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus. J Rheumatol 2008; 35:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/76\">",
"      Esdaile JM, Abrahamowicz M, Joseph L, et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996; 39:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/49/14106/abstract/77\">",
"      Vil&aacute; LM, Alarc&oacute;n GS, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol 2005; 32:2150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4670 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14106=[""].join("\n");
var outline_f13_49_14106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H268716918\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anemia of chronic inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Autoimmune hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Microangiopathic hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H83523360\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LEUKOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Decreased eosinophils and basophils",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LEUKOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Thrombocytopenia following splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      THROMBOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PANCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LYMPHADENOPATHY AND SPLENOMEGALY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ANTIBODIES TO CLOTTING FACTORS AND PHOSPHOLIPIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ERYTHROCYTE SEDIMENTATION RATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H268716918\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/4670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4670|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/4670|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/3/36924\" title=\"table 1\">",
"      Drugs associated with immune thrombocytopenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/15/20721?source=related_link\">",
"      Patient information: Anemia of chronic disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=related_link\">",
"      Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_49_14107="Histologic features of diffuse alveolar damage";
var content_f13_49_14107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic features of diffuse alveolar damage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Key histologic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uniform temporal appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alveolar septal thickening due to organizing fibrosis, usually diffuse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airspace organization (may be patchy or diffuse)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyaline membranes (may be focal or diffuse)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pertinent negative findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of granulomas, necrosis, or abscesses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of infectious agents (no viral inclusions and negative results with special stains for organisms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of prominent eosinophils and neutrophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negative cultures",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14107=[""].join("\n");
var outline_f13_49_14107=null;
var title_f13_49_14108="ACC AHA ESC manage AF in WPW";
var content_f13_49_14108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Management of atrial fibrillation (AF) in Wolff-Parkinson-White (WPW) preexcitation syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective for the management of AF in patients with WPW syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Catheter ablation of the accessory pathway in symptomatic patients, particularly those with syncope due to a rapid heart rate or a short refractory period in the bypass tract.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Immediate direct current (DC) cardioversion to prevent ventricular fibrillation in patients with a short refractory period in the bypass tract in whom AF occurs with a rapid ventricular response and hemodynamic instability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Intravenous procainamide or ibutilide to restore sinus rhythm when AF occurs in association with a wide QRS complex (&ge;120 msec) or a rapid preexcited ventricular response in patients who are hemodynamically stable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approach for the management of AF in patients with WPW syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Intravenous flecainide or DC cardioversion when rapid ventricular rates occur involving conduction over an accessory pathway.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following approach for the management of AF in patients with WPW syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Intravenous quinidine, procainamide, disopyramide, ibutilide, or amiodarone in hemodynamically stable patients with conduction over an accessory pathway.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approach is not useful or may be harmful for the management of AF in patients with WPW syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Intravenous digitalis or nondihydropyridine calcium channel blockers in patients with preexcited ventricular activation during AF.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14108=[""].join("\n");
var outline_f13_49_14108=null;
var title_f13_49_14109="Survival MI by gender";
var content_f13_49_14109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival after MI is lower in women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the RESCATE study of 331 women and 1129 men, the six-month survival after a first myocardial infarction (MI) was lower in women than men (74 versus 89 percent, p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Marrugate J, Sala J, Massia R, et al. for the RESCATE Investigators, JAMA 1998; 280:1405.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14109=[""].join("\n");
var outline_f13_49_14109=null;
var title_f13_49_14110="Survival with HMII versus medical management";
var content_f13_49_14110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F85808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F85808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Inference of survival benefit of current destination therapy with current continuous-flow left ventricular assist device (LVAD) compared with medical management from the REMATCH trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 404px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival of destination therapy with the current HeartMate II continuous-flow left ventricular assist device (LVAD) from the latest DT trial compared with medical management from the REMATCH trial.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Park SJ, Milano CA, Tatooles AJ,&nbsp;et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012; 5:241. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14110=[""].join("\n");
var outline_f13_49_14110=null;
var title_f13_49_14111="Paravertebral mass MRI I";
var content_f13_49_14111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Invasive neuroblastoma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T1-weighted section through the mass shows chest wall invasion (black arrow) and extension into the spinal canal (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_49_14111=[""].join("\n");
var outline_f13_49_14111=null;
